[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fXiKK5CMf1-I9ikNdTMzMgz84wmRuqkIJr8LXQP1MqjQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":80,"rows":87},"Chulalongkorn University",[4],306,false,48,26,39970,25,190,[14,17,20,23,25,27,29,31],{"name":15,"count":16},"Allergic Rhinitis",10,{"name":18,"count":19},"Acute Kidney Injury",7,{"name":21,"count":22},"Safety Issues",4,{"name":24,"count":22},"Obesity",{"name":26,"count":22},"Sepsis",{"name":28,"count":22},"Septic Shock",{"name":30,"count":22},"Hemodialysis",{"name":32,"count":22},"Lupus Nephritis",[34,39,44,48,53,57,62,67,71,76],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05360615","The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors","2024-06-01","Empagliflozin 10 MG",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06488326","Mulberry Leaf Extract Capsule on Blood Glucose Control in Healthy Volunteers","2024-12-30","Mulberry leaf extract 6 mg",{"nctId":45,"briefTitle":46,"date":42,"intervention":47},"NCT06476223","Artificial Saliva Containing Cumin and Ginger Extract in Hemodialysis Patients With Xerostomia","Artificial saliva containing cumin and ginger extract",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06482398","Cream Containing Sericin and Turmeric in Psoriasis Patients","2025-06-30","Sericin extract and turmeric extract cream",{"nctId":54,"briefTitle":55,"date":56,"intervention":38},"NCT06030843","The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1","2025-11-30",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05631405","Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)","2025-12-31","Dexamethasone",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT07439055","Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A","2026-03-01","Switching to low dose emicizumab",{"nctId":68,"briefTitle":69,"date":65,"intervention":70},"NCT06221553","Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG","B7H3 specific CAR T cell with IL-7Ra signaling domain",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT07012343","Exploring Different Dose-frequency Home Photodynamic Therapy Protocols Using a Novel Home-targeted LED Device for Onychomycosis","2026-06-30","urea 40% cream",{"nctId":77,"briefTitle":78,"date":74,"intervention":79},"NCT07031479","Efficacy of Itopride Versus Metoclopramide in Hospitalized Medicine Patients With High Gastric Residual Volume","Itopride HCI 50 mg",[81,82,83,84,85,86],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[88,117,140,158,190,212,243,272,295,321,346,368,394,420,453,475,499,517,535,560,578,598,620,638,661,679,721,760,794,819,843,867,895,913,939,957,983,1001,1024,1049,1077,1095,1113,1138,1156,1174,1192,1217,1244,1262,1287,1311,1329,1347,1371,1396,1421,1439,1464,1493,1511,1529,1547,1565,1590,1614,1632,1657,1675,1701,1719,1743,1761,1787,1805,1829,1852,1877,1906,1924,1949,1975,1993,2011,2036,2061,2086,2104,2130,2154,2172,2197,2222,2240,2267,2285,2312,2330,2353,2378,2396,2423,2441,2465,2491,2517,2535,2558,2583,2608,2626,2650,2675,2693,2724,2742,2765,2789,2813,2836,2866,2891,2931,2964,3003,3038,3063,3087,3113,3131,3149,3175,3193,3217,3235,3259,3277,3301,3326,3356,3374,3392,3410,3428,3446,3464,3487,3511,3536,3558,3576,3609,3631,3657,3675,3697,3715,3742,3760,3786,3810,3837,3855,3873],{"intervention":89,"totalTrials":90,"cells":91},"Tranexamic Acid",1,{"EARLY_PHASE1":92,"PHASE1":95,"PHASE2":97,"PHASE3":99,"PHASE4":101,"NA":115},{"trials":93,"activeCount":94},[],0,{"trials":96,"activeCount":94},[],{"trials":98,"activeCount":94},[],{"trials":100,"activeCount":94},[],{"trials":102,"activeCount":90,"soonestReadout":108},[103],{"nctId":104,"briefTitle":105,"status":106,"phases":107,"primaryCompletion":108,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":114},"NCT07078942","Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss in Pregnant Women Undergoing Cesarean Section","NOT_YET_RECRUITING",[85],"2026-07-31","2026-12-31","2025-07-20",98,[113],"Pregnant Women Undergoing Cesarean Delivery",[89],{"trials":116,"activeCount":94},[],{"intervention":79,"totalTrials":90,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":127,"NA":138},{"trials":120,"activeCount":94},[],{"trials":122,"activeCount":94},[],{"trials":124,"activeCount":94},[],{"trials":126,"activeCount":94},[],{"trials":128,"activeCount":90,"soonestReadout":74},[129],{"nctId":77,"briefTitle":78,"status":106,"phases":130,"primaryCompletion":74,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":136},[85],"2026-09-30","2025-07-01",86,[135],"Feeding Intolerance",[79,137],"Metoclopramide 10 mg ampoule",{"trials":139,"activeCount":94},[],{"intervention":137,"totalTrials":90,"cells":141},{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":150,"NA":156},{"trials":143,"activeCount":94},[],{"trials":145,"activeCount":94},[],{"trials":147,"activeCount":94},[],{"trials":149,"activeCount":94},[],{"trials":151,"activeCount":90,"soonestReadout":74},[152],{"nctId":77,"briefTitle":78,"status":106,"phases":153,"primaryCompletion":74,"completion":131,"start":132,"enrollment":133,"conditions":154,"interventions":155},[85],[135],[79,137],{"trials":157,"activeCount":94},[],{"intervention":38,"totalTrials":159,"cells":160},2,{"EARLY_PHASE1":161,"PHASE1":163,"PHASE2":174,"PHASE3":176,"PHASE4":186,"NA":188},{"trials":162,"activeCount":94},[],{"trials":164,"activeCount":90,"soonestReadout":37},[165],{"nctId":35,"briefTitle":36,"status":166,"phases":167,"primaryCompletion":37,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":173},"ACTIVE_NOT_RECRUITING",[82],"2026-07-01","2022-07-01",147,[172],"Empagliflozin in Post AKI Stage 2-3",[38],{"trials":175,"activeCount":94},[],{"trials":177,"activeCount":90,"soonestReadout":56},[178],{"nctId":54,"briefTitle":55,"status":179,"phases":180,"primaryCompletion":56,"completion":109,"start":181,"enrollment":182,"conditions":183,"interventions":185},"RECRUITING",[83,84],"2025-03-01",200,[184],"Empagliflozin in Cardiorenal Syndrome Type 1",[38],{"trials":187,"activeCount":94},[],{"trials":189,"activeCount":94},[],{"intervention":66,"totalTrials":90,"cells":191},{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":196,"PHASE3":198,"PHASE4":208,"NA":210},{"trials":193,"activeCount":94},[],{"trials":195,"activeCount":94},[],{"trials":197,"activeCount":94},[],{"trials":199,"activeCount":90,"soonestReadout":65},[200],{"nctId":63,"briefTitle":64,"status":166,"phases":201,"primaryCompletion":65,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":207},[83,84],"2026-04-01","2025-06-01",18,[206],"Hemophilia A Patient",[66],{"trials":209,"activeCount":94},[],{"trials":211,"activeCount":94},[],{"intervention":213,"totalTrials":159,"cells":214},"Drospirenone",{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":231,"PHASE4":233,"NA":235},{"trials":216,"activeCount":94},[],{"trials":218,"activeCount":94},[],{"trials":220,"activeCount":90,"soonestReadout":225},[221],{"nctId":222,"briefTitle":223,"status":179,"phases":224,"primaryCompletion":225,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":230},"NCT06345560","Pharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery Study",[82,83],"2026-07","2024-04-18",16,[229],"Contraception",[213],{"trials":232,"activeCount":94},[],{"trials":234,"activeCount":94},[],{"trials":236,"activeCount":90,"soonestReadout":225},[237],{"nctId":238,"briefTitle":239,"status":179,"phases":240,"primaryCompletion":225,"completion":225,"start":226,"enrollment":227,"conditions":241,"interventions":242},"NCT06345586","Drospirenone Only Pills and Cervical Mucus Changes: A Pre- and Post-Bariatric Surgery Study",[86],[229],[213],{"intervention":244,"totalTrials":90,"cells":245},"Transdermal Ethinyl Estradiol\u002FNorelgestromin Patch",{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":266,"PHASE4":268,"NA":270},{"trials":247,"activeCount":94},[],{"trials":249,"activeCount":94},[],{"trials":251,"activeCount":90,"soonestReadout":256},[252],{"nctId":253,"briefTitle":254,"status":179,"phases":255,"primaryCompletion":256,"completion":257,"start":258,"enrollment":259,"conditions":260,"interventions":265},"NCT07083635","Transdermal Ethinyl Estradiol and Norelgestromin for Irregular Bleeding in Contraceptive Implant Users",[83],"2026-09","2026-12","2025-07-29",40,[261,262,263,264],"Menstruation Disturbances","Metrorrhagia","Uterine Hemorrhage","Contraception Behavior",[244],{"trials":267,"activeCount":94},[],{"trials":269,"activeCount":94},[],{"trials":271,"activeCount":94},[],{"intervention":273,"totalTrials":90,"cells":274},"Cabozantinib",{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":276,"activeCount":94},[],{"trials":278,"activeCount":94},[],{"trials":280,"activeCount":90,"soonestReadout":225},[281],{"nctId":282,"briefTitle":283,"status":106,"phases":284,"primaryCompletion":225,"completion":257,"start":285,"enrollment":259,"conditions":286,"interventions":288},"NCT06535737","A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab",[83],"2024-08",[287],"Hepatocellular Carcinoma Non-resectable",[273],{"trials":290,"activeCount":94},[],{"trials":292,"activeCount":94},[],{"trials":294,"activeCount":94},[],{"intervention":296,"totalTrials":90,"cells":297},"Mulberry Leaf Extract",{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":313,"PHASE3":315,"PHASE4":317,"NA":319},{"trials":299,"activeCount":94},[],{"trials":301,"activeCount":90,"soonestReadout":306},[302],{"nctId":303,"briefTitle":304,"status":179,"phases":305,"primaryCompletion":306,"completion":307,"start":308,"enrollment":8,"conditions":309,"interventions":312},"NCT07532135","Safety of Mulberry Leaf Extract Capsule on Blood Glucose Control in Healthy Volunteer",[82],"2026-09-01","2026-09-24","2025-10-01",[310,311],"Healthy Volunteers","Non Diabetic Hyperglycemia",[296],{"trials":314,"activeCount":94},[],{"trials":316,"activeCount":94},[],{"trials":318,"activeCount":94},[],{"trials":320,"activeCount":94},[],{"intervention":322,"totalTrials":90,"cells":323},"CD19-IL7Ra CAR-T cells",{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":338,"PHASE3":340,"PHASE4":342,"NA":344},{"trials":325,"activeCount":94},[],{"trials":327,"activeCount":90,"soonestReadout":306},[328],{"nctId":329,"briefTitle":330,"status":179,"phases":331,"primaryCompletion":306,"completion":332,"start":333,"enrollment":227,"conditions":334,"interventions":337},"NCT07078929","Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)",[82],"2028-09-01","2026-01-01",[335,336],"Relapse B Acute Lymphoblastic Leukemia","Refactory Childhood Acute Lymphoblastic Leukemia",[322],{"trials":339,"activeCount":94},[],{"trials":341,"activeCount":94},[],{"trials":343,"activeCount":94},[],{"trials":345,"activeCount":94},[],{"intervention":70,"totalTrials":90,"cells":347},{"EARLY_PHASE1":348,"PHASE1":350,"PHASE2":360,"PHASE3":362,"PHASE4":364,"NA":366},{"trials":349,"activeCount":94},[],{"trials":351,"activeCount":90,"soonestReadout":65},[352],{"nctId":68,"briefTitle":69,"status":179,"phases":353,"primaryCompletion":65,"completion":306,"start":354,"enrollment":355,"conditions":356,"interventions":359},[82],"2024-03-01",9,[357,358],"DIPG Brain Tumor","Diffuse Intrinsic Pontine Glioma",[70],{"trials":361,"activeCount":94},[],{"trials":363,"activeCount":94},[],{"trials":365,"activeCount":94},[],{"trials":367,"activeCount":94},[],{"intervention":369,"totalTrials":90,"cells":370},"B7H3-IL7Ra CAR-T cells",{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":386,"PHASE3":388,"PHASE4":390,"NA":392},{"trials":372,"activeCount":94},[],{"trials":374,"activeCount":90,"soonestReadout":379},[375],{"nctId":376,"briefTitle":377,"status":179,"phases":378,"primaryCompletion":379,"completion":380,"start":381,"enrollment":355,"conditions":382,"interventions":385},"NCT06612645","Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors",[82],"2027-12-01","2028-12-01","2025-04-01",[383,384],"Pediatric Cancers","Solid Tumor Pediatric",[369],{"trials":387,"activeCount":94},[],{"trials":389,"activeCount":94},[],{"trials":391,"activeCount":94},[],{"trials":393,"activeCount":94},[],{"intervention":395,"totalTrials":90,"cells":396},"Chimeric Antigen Receptor T Cells",{"EARLY_PHASE1":397,"PHASE1":410,"PHASE2":412,"PHASE3":414,"PHASE4":416,"NA":418},{"trials":398,"activeCount":90,"soonestReadout":403},[399],{"nctId":400,"briefTitle":401,"status":106,"phases":402,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":409},"NCT07458659","Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed\u002FRefractory Multiple Myeloma",[81],"2028-06-01","2029-06-01","2026-06-01",3,[408],"Relapsed\u002FRefractory Multiple Myeloma (MM)",[395],{"trials":411,"activeCount":94},[],{"trials":413,"activeCount":94},[],{"trials":415,"activeCount":94},[],{"trials":417,"activeCount":94},[],{"trials":419,"activeCount":94},[],{"intervention":61,"totalTrials":159,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":439,"PHASE3":441,"PHASE4":443,"NA":445},{"trials":423,"activeCount":94},[],{"trials":425,"activeCount":94},[426],{"nctId":427,"briefTitle":428,"status":429,"phases":430,"primaryCompletion":431,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":438},"NCT05841121","Antenatal Dexamethasone for Late Preterm Deliveries","UNKNOWN",[82],"2024-03-28","2024-04-30","2023-08-25",294,[436,437],"Respiratory Distress of Newborn","Preterm Birth",[61],{"trials":440,"activeCount":94},[],{"trials":442,"activeCount":94},[],{"trials":444,"activeCount":94},[],{"trials":446,"activeCount":90,"soonestReadout":60},[447],{"nctId":58,"briefTitle":59,"status":179,"phases":448,"primaryCompletion":60,"completion":109,"start":449,"enrollment":182,"conditions":450,"interventions":452},[86],"2022-10-16",[451],"Severe Dengue",[61],{"intervention":75,"totalTrials":90,"cells":454},{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":461,"PHASE4":463,"NA":465},{"trials":456,"activeCount":94},[],{"trials":458,"activeCount":94},[],{"trials":460,"activeCount":94},[],{"trials":462,"activeCount":94},[],{"trials":464,"activeCount":94},[],{"trials":466,"activeCount":90,"soonestReadout":74},[467],{"nctId":72,"briefTitle":73,"status":166,"phases":468,"primaryCompletion":74,"completion":109,"start":469,"enrollment":470,"conditions":471,"interventions":474},[86],"2025-01-13",50,[472,473],"Onychomycosis of Toenails","Onychomycosis of Fingernail",[75],{"intervention":43,"totalTrials":90,"cells":476},{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":485,"NA":487},{"trials":478,"activeCount":94},[],{"trials":480,"activeCount":94},[],{"trials":482,"activeCount":94},[],{"trials":484,"activeCount":94},[],{"trials":486,"activeCount":94},[],{"trials":488,"activeCount":90,"soonestReadout":42},[489],{"nctId":40,"briefTitle":41,"status":106,"phases":490,"primaryCompletion":42,"completion":491,"start":492,"enrollment":493,"conditions":494,"interventions":496},[86],"2025-02-25","2024-07-01",56,[495],"Health, Subjective",[43,497,498],"Mulberry leaf extract 12 mg","Mulberry leaf extract 18 mg",{"intervention":497,"totalTrials":90,"cells":500},{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":509,"NA":511},{"trials":502,"activeCount":94},[],{"trials":504,"activeCount":94},[],{"trials":506,"activeCount":94},[],{"trials":508,"activeCount":94},[],{"trials":510,"activeCount":94},[],{"trials":512,"activeCount":90,"soonestReadout":42},[513],{"nctId":40,"briefTitle":41,"status":106,"phases":514,"primaryCompletion":42,"completion":491,"start":492,"enrollment":493,"conditions":515,"interventions":516},[86],[495],[43,497,498],{"intervention":498,"totalTrials":90,"cells":518},{"EARLY_PHASE1":519,"PHASE1":521,"PHASE2":523,"PHASE3":525,"PHASE4":527,"NA":529},{"trials":520,"activeCount":94},[],{"trials":522,"activeCount":94},[],{"trials":524,"activeCount":94},[],{"trials":526,"activeCount":94},[],{"trials":528,"activeCount":94},[],{"trials":530,"activeCount":90,"soonestReadout":42},[531],{"nctId":40,"briefTitle":41,"status":106,"phases":532,"primaryCompletion":42,"completion":491,"start":492,"enrollment":493,"conditions":533,"interventions":534},[86],[495],[43,497,498],{"intervention":536,"totalTrials":90,"cells":537},"Local PEG4000",{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":544,"PHASE4":546,"NA":548},{"trials":539,"activeCount":94},[],{"trials":541,"activeCount":94},[],{"trials":543,"activeCount":94},[],{"trials":545,"activeCount":94},[],{"trials":547,"activeCount":94},[],{"trials":549,"activeCount":90,"soonestReadout":257},[550],{"nctId":551,"briefTitle":552,"status":179,"phases":553,"primaryCompletion":257,"completion":257,"start":554,"enrollment":555,"conditions":556,"interventions":558},"NCT06357897","The Efficacy and Palatability of Developed Polyethylene Glycol-based Formula for Children With Functional Constipation",[86],"2024-05-03",52,[557],"Functional Constipation",[536,559],"Commercial PEG4000",{"intervention":559,"totalTrials":90,"cells":561},{"EARLY_PHASE1":562,"PHASE1":564,"PHASE2":566,"PHASE3":568,"PHASE4":570,"NA":572},{"trials":563,"activeCount":94},[],{"trials":565,"activeCount":94},[],{"trials":567,"activeCount":94},[],{"trials":569,"activeCount":94},[],{"trials":571,"activeCount":94},[],{"trials":573,"activeCount":90,"soonestReadout":257},[574],{"nctId":551,"briefTitle":552,"status":179,"phases":575,"primaryCompletion":257,"completion":257,"start":554,"enrollment":555,"conditions":576,"interventions":577},[86],[557],[536,559],{"intervention":47,"totalTrials":90,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":586,"PHASE4":588,"NA":590},{"trials":581,"activeCount":94},[],{"trials":583,"activeCount":94},[],{"trials":585,"activeCount":94},[],{"trials":587,"activeCount":94},[],{"trials":589,"activeCount":94},[],{"trials":591,"activeCount":90,"soonestReadout":42},[592],{"nctId":45,"briefTitle":46,"status":106,"phases":593,"primaryCompletion":42,"completion":594,"start":492,"enrollment":9,"conditions":595,"interventions":597},[86],"2025-01-31",[596],"Xerostomia",[47],{"intervention":52,"totalTrials":90,"cells":599},{"EARLY_PHASE1":600,"PHASE1":602,"PHASE2":604,"PHASE3":606,"PHASE4":608,"NA":610},{"trials":601,"activeCount":94},[],{"trials":603,"activeCount":94},[],{"trials":605,"activeCount":94},[],{"trials":607,"activeCount":94},[],{"trials":609,"activeCount":94},[],{"trials":611,"activeCount":90,"soonestReadout":51},[612],{"nctId":49,"briefTitle":50,"status":106,"phases":613,"primaryCompletion":51,"completion":614,"start":492,"enrollment":615,"conditions":616,"interventions":618},[86],"2025-07-31",30,[617],"Psoriasis",[52,619],"Triamcinolone acetonide 1% Cream",{"intervention":619,"totalTrials":90,"cells":621},{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":630,"NA":632},{"trials":623,"activeCount":94},[],{"trials":625,"activeCount":94},[],{"trials":627,"activeCount":94},[],{"trials":629,"activeCount":94},[],{"trials":631,"activeCount":94},[],{"trials":633,"activeCount":90,"soonestReadout":51},[634],{"nctId":49,"briefTitle":50,"status":106,"phases":635,"primaryCompletion":51,"completion":614,"start":492,"enrollment":615,"conditions":636,"interventions":637},[86],[617],[52,619],{"intervention":639,"totalTrials":90,"cells":640},"Curcumin in Nanogels",{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":647,"PHASE4":649,"NA":651},{"trials":642,"activeCount":94},[],{"trials":644,"activeCount":94},[],{"trials":646,"activeCount":94},[],{"trials":648,"activeCount":94},[],{"trials":650,"activeCount":94},[],{"trials":652,"activeCount":90,"soonestReadout":74},[653],{"nctId":654,"briefTitle":655,"status":179,"phases":656,"primaryCompletion":74,"completion":74,"start":203,"enrollment":615,"conditions":657,"interventions":659},"NCT06932848","The Therapeutic Effect of Curcumin in Nanogels Compared to 0.1% FAO in the Management of Oral Lichen Planus",[86],[658],"Oral Lichen Planus",[639,660],"0.1% Fluocinolone Acetonide Oral Paste",{"intervention":660,"totalTrials":90,"cells":662},{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":671,"NA":673},{"trials":664,"activeCount":94},[],{"trials":666,"activeCount":94},[],{"trials":668,"activeCount":94},[],{"trials":670,"activeCount":94},[],{"trials":672,"activeCount":94},[],{"trials":674,"activeCount":90,"soonestReadout":74},[675],{"nctId":654,"briefTitle":655,"status":179,"phases":676,"primaryCompletion":74,"completion":74,"start":203,"enrollment":615,"conditions":677,"interventions":678},[86],[658],[639,660],{"intervention":680,"totalTrials":159,"cells":681},"Normal saline",{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":686,"PHASE3":688,"PHASE4":702,"NA":719},{"trials":683,"activeCount":94},[],{"trials":685,"activeCount":94},[],{"trials":687,"activeCount":94},[],{"trials":689,"activeCount":94},[690],{"nctId":691,"briefTitle":692,"status":693,"phases":694,"primaryCompletion":695,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":700},"NCT03277677","The Effect of Fluid Resuscitation With 0.9% Sodium Chloride Versus Balanced Crystalloid Solution on Renal Function of Sepsis Patients","COMPLETED",[84],"2018-07-01","2021-03-01","2017-07-01",116,[26,28,18],[680,701],"Ringer's Acetate",{"trials":703,"activeCount":94},[704],{"nctId":705,"briefTitle":706,"status":693,"phases":707,"primaryCompletion":708,"completion":708,"start":709,"enrollment":710,"conditions":711,"interventions":715},"NCT01281501","Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole",[85],"2011-10","2011-01",87,[712,713,714],"Dyspepsia","Emergency","Pain",[680,716,717,718],"Pantoprazole","Oral antacid","Hyoscine butylbromide",{"trials":720,"activeCount":94},[],{"intervention":722,"totalTrials":159,"cells":723},"Enalapril plus Losartan",{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":730,"PHASE4":732,"NA":758},{"trials":725,"activeCount":94},[],{"trials":727,"activeCount":94},[],{"trials":729,"activeCount":94},[],{"trials":731,"activeCount":94},[],{"trials":733,"activeCount":94},[734,746],{"nctId":735,"briefTitle":736,"status":429,"phases":737,"primaryCompletion":738,"completion":708,"start":739,"enrollment":740,"conditions":741,"interventions":743},"NCT01305850","The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients",[85],"2011-08","2010-07",100,[742],"Peritoneal Membrane Failure",[744,745,722],"Aliskiren","Aliskiren plus Losartan",{"nctId":747,"briefTitle":748,"status":429,"phases":749,"primaryCompletion":750,"completion":751,"start":752,"enrollment":753,"conditions":754,"interventions":756},"NCT01041963","The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients",[85],"2010-06","2010-09","2009-06",90,[755],"Continuous Ambulatory Peritoneal Dialysis",[757,722],"Enalapril",{"trials":759,"activeCount":94},[],{"intervention":761,"totalTrials":159,"cells":762},"Mycophenolate mofetil",{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":769,"PHASE4":780,"NA":792},{"trials":764,"activeCount":94},[],{"trials":766,"activeCount":94},[],{"trials":768,"activeCount":94},[],{"trials":770,"activeCount":94},[771],{"nctId":772,"briefTitle":773,"status":693,"phases":774,"primaryCompletion":775,"completion":775,"start":776,"enrollment":777,"conditions":778,"interventions":779},"NCT01042457","Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis",[84],"2011-12","2009-05",24,[32],[761],{"trials":781,"activeCount":94},[782],{"nctId":783,"briefTitle":784,"status":785,"phases":786,"primaryCompletion":787,"completion":787,"start":788,"enrollment":159,"conditions":789,"interventions":790},"NCT03920059","Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis","TERMINATED",[85],"2020-01-30","2019-08-20",[32],[791],"Mycophenolate Mofetil",{"trials":793,"activeCount":94},[],{"intervention":795,"totalTrials":90,"cells":796},"Cholecalciferol",{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":803,"PHASE4":805,"NA":817},{"trials":798,"activeCount":94},[],{"trials":800,"activeCount":94},[],{"trials":802,"activeCount":94},[],{"trials":804,"activeCount":94},[],{"trials":806,"activeCount":94},[807],{"nctId":808,"briefTitle":809,"status":693,"phases":810,"primaryCompletion":811,"completion":811,"start":812,"enrollment":813,"conditions":814,"interventions":816},"NCT02890823","Effect of Three Different Doses of Oral Cholecalciferol on 25-Hydroxyvitamin D Changes Among Epilepsy Patients With Hypovitaminosis D",[85],"2016-03","2015-07",210,[815],"Epilepsy",[795],{"trials":818,"activeCount":94},[],{"intervention":820,"totalTrials":90,"cells":821},"Verorab®",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":828,"PHASE4":830,"NA":841},{"trials":823,"activeCount":94},[],{"trials":825,"activeCount":94},[],{"trials":827,"activeCount":94},[],{"trials":829,"activeCount":94},[],{"trials":831,"activeCount":94},[832],{"nctId":833,"briefTitle":834,"status":429,"phases":835,"primaryCompletion":836,"completion":836,"start":837,"enrollment":259,"conditions":838,"interventions":840},"NCT02490956","Diagnostic Immunization With Rabies Vaccine in Patients With PID",[85],"2016-09","2015-04",[839],"Primary Immunodeficiency",[820],{"trials":842,"activeCount":94},[],{"intervention":844,"totalTrials":90,"cells":845},"Rotigotine",{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":854,"NA":865},{"trials":847,"activeCount":94},[],{"trials":849,"activeCount":94},[],{"trials":851,"activeCount":94},[],{"trials":853,"activeCount":94},[],{"trials":855,"activeCount":94},[856],{"nctId":857,"briefTitle":858,"status":429,"phases":859,"primaryCompletion":860,"completion":861,"start":836,"enrollment":259,"conditions":862,"interventions":864},"NCT03098368","Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors",[85],"2017-12","2018-05",[863],"Nocturnal Hypokinesia",[844],{"trials":866,"activeCount":94},[],{"intervention":868,"totalTrials":90,"cells":869},"Etonogestrel Drug Implant",{"EARLY_PHASE1":870,"PHASE1":872,"PHASE2":874,"PHASE3":876,"PHASE4":878,"NA":893},{"trials":871,"activeCount":94},[],{"trials":873,"activeCount":94},[],{"trials":875,"activeCount":94},[],{"trials":877,"activeCount":94},[],{"trials":879,"activeCount":94},[880],{"nctId":881,"briefTitle":882,"status":693,"phases":883,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":888,"interventions":891},"NCT03353012","Acceptability & Tolerance of Immediate Versus Delayed Postpartum Contraceptive Implant",[85],"2018-05-01","2018-08-01","2018-01-01",60,[889,890],"Breastfeeding","Post Partum",[868,892],"Levonorgestrel Drug Implant",{"trials":894,"activeCount":94},[],{"intervention":892,"totalTrials":90,"cells":896},{"EARLY_PHASE1":897,"PHASE1":899,"PHASE2":901,"PHASE3":903,"PHASE4":905,"NA":911},{"trials":898,"activeCount":94},[],{"trials":900,"activeCount":94},[],{"trials":902,"activeCount":94},[],{"trials":904,"activeCount":94},[],{"trials":906,"activeCount":94},[907],{"nctId":881,"briefTitle":882,"status":693,"phases":908,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":909,"interventions":910},[85],[889,890],[868,892],{"trials":912,"activeCount":94},[],{"intervention":914,"totalTrials":90,"cells":915},"Diazepam",{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":922,"PHASE4":924,"NA":937},{"trials":917,"activeCount":94},[],{"trials":919,"activeCount":94},[],{"trials":921,"activeCount":94},[],{"trials":923,"activeCount":94},[],{"trials":925,"activeCount":94},[926],{"nctId":927,"briefTitle":928,"status":693,"phases":929,"primaryCompletion":930,"completion":930,"start":931,"enrollment":932,"conditions":933,"interventions":935},"NCT01939093","Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis",[85],"2011-09","2010-03",80,[934],"Methamphetamine-induced Psychosis",[914,936],"Stugeron",{"trials":938,"activeCount":94},[],{"intervention":936,"totalTrials":90,"cells":940},{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":947,"PHASE4":949,"NA":955},{"trials":942,"activeCount":94},[],{"trials":944,"activeCount":94},[],{"trials":946,"activeCount":94},[],{"trials":948,"activeCount":94},[],{"trials":950,"activeCount":94},[951],{"nctId":927,"briefTitle":928,"status":693,"phases":952,"primaryCompletion":930,"completion":930,"start":931,"enrollment":932,"conditions":953,"interventions":954},[85],[934],[914,936],{"trials":956,"activeCount":94},[],{"intervention":958,"totalTrials":90,"cells":959},"Cefepime",{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":966,"PHASE4":968,"NA":981},{"trials":961,"activeCount":94},[],{"trials":963,"activeCount":94},[],{"trials":965,"activeCount":94},[],{"trials":967,"activeCount":94},[],{"trials":969,"activeCount":94},[970],{"nctId":971,"briefTitle":972,"status":693,"phases":973,"primaryCompletion":974,"completion":974,"start":975,"enrollment":976,"conditions":977,"interventions":979},"NCT02872038","Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis",[85],"2016-11-30","2015-08",154,[978],"Peritoneal Dialysis Associated Peritonitis",[958,980],"Cefazolin plus Ceftazidime",{"trials":982,"activeCount":94},[],{"intervention":980,"totalTrials":90,"cells":984},{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":991,"PHASE4":993,"NA":999},{"trials":986,"activeCount":94},[],{"trials":988,"activeCount":94},[],{"trials":990,"activeCount":94},[],{"trials":992,"activeCount":94},[],{"trials":994,"activeCount":94},[995],{"nctId":971,"briefTitle":972,"status":693,"phases":996,"primaryCompletion":974,"completion":974,"start":975,"enrollment":976,"conditions":997,"interventions":998},[85],[978],[958,980],{"trials":1000,"activeCount":94},[],{"intervention":1002,"totalTrials":90,"cells":1003},"FVIII",{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1010,"PHASE4":1012,"NA":1022},{"trials":1005,"activeCount":94},[],{"trials":1007,"activeCount":94},[],{"trials":1009,"activeCount":94},[],{"trials":1011,"activeCount":94},[],{"trials":1013,"activeCount":94},[1014],{"nctId":1015,"briefTitle":1016,"status":693,"phases":1017,"primaryCompletion":811,"completion":811,"start":1018,"enrollment":227,"conditions":1019,"interventions":1021},"NCT02727647","Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients",[85],"2015-05",[1020],"Hemophilia A",[1002,1002],{"trials":1023,"activeCount":94},[],{"intervention":1025,"totalTrials":90,"cells":1026},"Micronized progesterone",{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1031,"PHASE3":1033,"PHASE4":1035,"NA":1047},{"trials":1028,"activeCount":94},[],{"trials":1030,"activeCount":94},[],{"trials":1032,"activeCount":94},[],{"trials":1034,"activeCount":94},[],{"trials":1036,"activeCount":94},[1037],{"nctId":1038,"briefTitle":1039,"status":429,"phases":1040,"primaryCompletion":1041,"completion":1042,"start":1043,"enrollment":8,"conditions":1044,"interventions":1046},"NCT05997563","Adjunctive Vaginal Progesterone in Management of Preterm Labor",[85],"2025-08-31","2025-10-31","2023-08-16",[1045],"Preterm Labor",[1025],{"trials":1048,"activeCount":94},[],{"intervention":1050,"totalTrials":90,"cells":1051},"Pregabalin",{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1058,"PHASE4":1060,"NA":1075},{"trials":1053,"activeCount":94},[],{"trials":1055,"activeCount":94},[],{"trials":1057,"activeCount":94},[],{"trials":1059,"activeCount":94},[],{"trials":1061,"activeCount":94},[1062],{"nctId":1063,"briefTitle":1064,"status":693,"phases":1065,"primaryCompletion":1066,"completion":1067,"start":1068,"enrollment":740,"conditions":1069,"interventions":1072},"NCT01344213","Pregabalin, Celecoxib, Total Knee Arthroplasty and Intrathecal Morphine",[85],"2009-10","2010-10","2008-07",[1070,1071],"Postoperative Pain Management","Total Knee Arthroplasty",[1050,1073,1074],"Celecoxib","Pregabalin with celecoxib",{"trials":1076,"activeCount":94},[],{"intervention":1073,"totalTrials":90,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1085,"PHASE4":1087,"NA":1093},{"trials":1080,"activeCount":94},[],{"trials":1082,"activeCount":94},[],{"trials":1084,"activeCount":94},[],{"trials":1086,"activeCount":94},[],{"trials":1088,"activeCount":94},[1089],{"nctId":1063,"briefTitle":1064,"status":693,"phases":1090,"primaryCompletion":1066,"completion":1067,"start":1068,"enrollment":740,"conditions":1091,"interventions":1092},[85],[1070,1071],[1050,1073,1074],{"trials":1094,"activeCount":94},[],{"intervention":1074,"totalTrials":90,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1103,"PHASE4":1105,"NA":1111},{"trials":1098,"activeCount":94},[],{"trials":1100,"activeCount":94},[],{"trials":1102,"activeCount":94},[],{"trials":1104,"activeCount":94},[],{"trials":1106,"activeCount":94},[1107],{"nctId":1063,"briefTitle":1064,"status":693,"phases":1108,"primaryCompletion":1066,"completion":1067,"start":1068,"enrollment":740,"conditions":1109,"interventions":1110},[85],[1070,1071],[1050,1073,1074],{"trials":1112,"activeCount":94},[],{"intervention":1114,"totalTrials":90,"cells":1115},"Testosterone Undecanoate,1000mg",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1124,"NA":1136},{"trials":1117,"activeCount":94},[],{"trials":1119,"activeCount":94},[],{"trials":1121,"activeCount":94},[],{"trials":1123,"activeCount":94},[],{"trials":1125,"activeCount":94},[1126],{"nctId":1127,"briefTitle":1128,"status":693,"phases":1129,"primaryCompletion":709,"completion":1130,"start":1131,"enrollment":615,"conditions":1132,"interventions":1135},"NCT00421460","The Therapy of Nebido as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction",[85],"2011-05","2007-01",[1133,1134],"Hypogonadism","Erectile Dysfunction",[1114],{"trials":1137,"activeCount":94},[],{"intervention":716,"totalTrials":90,"cells":1139},{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1144,"PHASE3":1146,"PHASE4":1148,"NA":1154},{"trials":1141,"activeCount":94},[],{"trials":1143,"activeCount":94},[],{"trials":1145,"activeCount":94},[],{"trials":1147,"activeCount":94},[],{"trials":1149,"activeCount":94},[1150],{"nctId":705,"briefTitle":706,"status":693,"phases":1151,"primaryCompletion":708,"completion":708,"start":709,"enrollment":710,"conditions":1152,"interventions":1153},[85],[712,713,714],[680,716,717,718],{"trials":1155,"activeCount":94},[],{"intervention":717,"totalTrials":90,"cells":1157},{"EARLY_PHASE1":1158,"PHASE1":1160,"PHASE2":1162,"PHASE3":1164,"PHASE4":1166,"NA":1172},{"trials":1159,"activeCount":94},[],{"trials":1161,"activeCount":94},[],{"trials":1163,"activeCount":94},[],{"trials":1165,"activeCount":94},[],{"trials":1167,"activeCount":94},[1168],{"nctId":705,"briefTitle":706,"status":693,"phases":1169,"primaryCompletion":708,"completion":708,"start":709,"enrollment":710,"conditions":1170,"interventions":1171},[85],[712,713,714],[680,716,717,718],{"trials":1173,"activeCount":94},[],{"intervention":718,"totalTrials":90,"cells":1175},{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1182,"PHASE4":1184,"NA":1190},{"trials":1177,"activeCount":94},[],{"trials":1179,"activeCount":94},[],{"trials":1181,"activeCount":94},[],{"trials":1183,"activeCount":94},[],{"trials":1185,"activeCount":94},[1186],{"nctId":705,"briefTitle":706,"status":693,"phases":1187,"primaryCompletion":708,"completion":708,"start":709,"enrollment":710,"conditions":1188,"interventions":1189},[85],[712,713,714],[680,716,717,718],{"trials":1191,"activeCount":94},[],{"intervention":1193,"totalTrials":90,"cells":1194},"Banana Blossom",{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1201,"PHASE4":1203,"NA":1215},{"trials":1196,"activeCount":94},[],{"trials":1198,"activeCount":94},[],{"trials":1200,"activeCount":94},[],{"trials":1202,"activeCount":94},[],{"trials":1204,"activeCount":94},[1205],{"nctId":1206,"briefTitle":1207,"status":693,"phases":1208,"primaryCompletion":1209,"completion":1209,"start":1210,"enrollment":1211,"conditions":1212,"interventions":1214},"NCT05465460","Effect of Banana Blossom on Breast Milk Volume in Mothers of Preterm Newborns",[85],"2023-08-31","2022-07-13",70,[437,1213],"Postpartum Women",[1193],{"trials":1216,"activeCount":94},[],{"intervention":1218,"totalTrials":90,"cells":1219},"Extended half-life FVIII concentrates with PK-guided dosing",{"EARLY_PHASE1":1220,"PHASE1":1222,"PHASE2":1224,"PHASE3":1226,"PHASE4":1228,"NA":1242},{"trials":1221,"activeCount":94},[],{"trials":1223,"activeCount":94},[],{"trials":1225,"activeCount":94},[],{"trials":1227,"activeCount":94},[],{"trials":1229,"activeCount":94},[1230],{"nctId":1231,"briefTitle":1232,"status":693,"phases":1233,"primaryCompletion":1234,"completion":1235,"start":1236,"enrollment":1237,"conditions":1238,"interventions":1240},"NCT05281185","Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A",[85],"2022-03-31","2022-04-30","2021-07-01",15,[1239],"Severe Hemophilia A Without Inhibitor",[1218,1241],"standard half-life FVIII concentrates with weight-based dosing",{"trials":1243,"activeCount":94},[],{"intervention":1241,"totalTrials":90,"cells":1245},{"EARLY_PHASE1":1246,"PHASE1":1248,"PHASE2":1250,"PHASE3":1252,"PHASE4":1254,"NA":1260},{"trials":1247,"activeCount":94},[],{"trials":1249,"activeCount":94},[],{"trials":1251,"activeCount":94},[],{"trials":1253,"activeCount":94},[],{"trials":1255,"activeCount":94},[1256],{"nctId":1231,"briefTitle":1232,"status":693,"phases":1257,"primaryCompletion":1234,"completion":1235,"start":1236,"enrollment":1237,"conditions":1258,"interventions":1259},[85],[1239],[1218,1241],{"trials":1261,"activeCount":94},[],{"intervention":1263,"totalTrials":90,"cells":1264},"Ergocalciferol",{"EARLY_PHASE1":1265,"PHASE1":1267,"PHASE2":1269,"PHASE3":1271,"PHASE4":1273,"NA":1285},{"trials":1266,"activeCount":94},[],{"trials":1268,"activeCount":94},[],{"trials":1270,"activeCount":94},[],{"trials":1272,"activeCount":94},[],{"trials":1274,"activeCount":94},[1275],{"nctId":1276,"briefTitle":1277,"status":429,"phases":1278,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":1282,"interventions":1284},"NCT03228862","Optimal Doses of Ergocalciferol Supplementation for Treatment of Hypovitaminosis D in Adults",[85],"2018-02-01","2017-05-01",360,[1283],"Vitamin D2 Supplementation in Vitamin D Insufficiency",[1263],{"trials":1286,"activeCount":94},[],{"intervention":1288,"totalTrials":90,"cells":1289},"calcium sensing receptor agonist",{"EARLY_PHASE1":1290,"PHASE1":1292,"PHASE2":1294,"PHASE3":1296,"PHASE4":1298,"NA":1309},{"trials":1291,"activeCount":94},[],{"trials":1293,"activeCount":94},[],{"trials":1295,"activeCount":94},[],{"trials":1297,"activeCount":94},[],{"trials":1299,"activeCount":94},[1300],{"nctId":1301,"briefTitle":1302,"status":693,"phases":1303,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":887,"conditions":1306,"interventions":1308},"NCT02056730","The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid",[85],"2015-02","2013-11",[1307],"Hyperparathyroidism, Secondary",[1288],{"trials":1310,"activeCount":94},[],{"intervention":744,"totalTrials":90,"cells":1312},{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1319,"PHASE4":1321,"NA":1327},{"trials":1314,"activeCount":94},[],{"trials":1316,"activeCount":94},[],{"trials":1318,"activeCount":94},[],{"trials":1320,"activeCount":94},[],{"trials":1322,"activeCount":94},[1323],{"nctId":735,"briefTitle":736,"status":429,"phases":1324,"primaryCompletion":738,"completion":708,"start":739,"enrollment":740,"conditions":1325,"interventions":1326},[85],[742],[744,745,722],{"trials":1328,"activeCount":94},[],{"intervention":745,"totalTrials":90,"cells":1330},{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1337,"PHASE4":1339,"NA":1345},{"trials":1332,"activeCount":94},[],{"trials":1334,"activeCount":94},[],{"trials":1336,"activeCount":94},[],{"trials":1338,"activeCount":94},[],{"trials":1340,"activeCount":94},[1341],{"nctId":735,"briefTitle":736,"status":429,"phases":1342,"primaryCompletion":738,"completion":708,"start":739,"enrollment":740,"conditions":1343,"interventions":1344},[85],[742],[744,745,722],{"trials":1346,"activeCount":94},[],{"intervention":1348,"totalTrials":90,"cells":1349},"0.5% carboxymethylcellulose (CMC) with purite and CMC alone",{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1356,"PHASE4":1358,"NA":1369},{"trials":1351,"activeCount":94},[],{"trials":1353,"activeCount":94},[],{"trials":1355,"activeCount":94},[],{"trials":1357,"activeCount":94},[],{"trials":1359,"activeCount":94},[1360],{"nctId":1361,"briefTitle":1362,"status":693,"phases":1363,"completion":1364,"start":1365,"enrollment":740,"conditions":1366,"interventions":1368},"NCT00386646","Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye",[85],"2005-10","2004-02",[1367],"Dry Eye Syndromes",[1348],{"trials":1370,"activeCount":94},[],{"intervention":1372,"totalTrials":90,"cells":1373},"Dexmedetomidine",{"EARLY_PHASE1":1374,"PHASE1":1376,"PHASE2":1378,"PHASE3":1380,"PHASE4":1382,"NA":1394},{"trials":1375,"activeCount":94},[],{"trials":1377,"activeCount":94},[],{"trials":1379,"activeCount":94},[],{"trials":1381,"activeCount":94},[],{"trials":1383,"activeCount":94},[1384],{"nctId":1385,"briefTitle":1386,"status":693,"phases":1387,"primaryCompletion":1388,"completion":1388,"start":1389,"enrollment":740,"conditions":1390,"interventions":1393},"NCT03054857","The Effect of Dexmedetomidine Infusion on Post-operative Cognitive Function and Oxidative Stress in Cardiac Surgery",[85],"2016-12","2015-06",[1391,1392],"Oxidative Stress","Cognition Disorders",[1372],{"trials":1395,"activeCount":94},[],{"intervention":1397,"totalTrials":90,"cells":1398},"combination between moderate to vigorous-intensity physical activities and pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis",{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1405,"PHASE4":1407,"NA":1419},{"trials":1400,"activeCount":94},[],{"trials":1402,"activeCount":94},[],{"trials":1404,"activeCount":94},[],{"trials":1406,"activeCount":94},[],{"trials":1408,"activeCount":94},[1409],{"nctId":1410,"briefTitle":1411,"status":693,"phases":1412,"primaryCompletion":1413,"completion":1413,"start":169,"enrollment":1414,"conditions":1415,"interventions":1417},"NCT05728528","Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients",[85],"2022-12-31",13,[1416],"Hemophilia",[1397,1418],"pharmacokinetic-guided extended half-life FVIII concentrates prophylaxis alone",{"trials":1420,"activeCount":94},[],{"intervention":1418,"totalTrials":90,"cells":1422},{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1429,"PHASE4":1431,"NA":1437},{"trials":1424,"activeCount":94},[],{"trials":1426,"activeCount":94},[],{"trials":1428,"activeCount":94},[],{"trials":1430,"activeCount":94},[],{"trials":1432,"activeCount":94},[1433],{"nctId":1410,"briefTitle":1411,"status":693,"phases":1434,"primaryCompletion":1413,"completion":1413,"start":169,"enrollment":1414,"conditions":1435,"interventions":1436},[85],[1416],[1397,1418],{"trials":1438,"activeCount":94},[],{"intervention":1440,"totalTrials":90,"cells":1441},"Ginger",{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1448,"PHASE4":1450,"NA":1462},{"trials":1443,"activeCount":94},[],{"trials":1445,"activeCount":94},[],{"trials":1447,"activeCount":94},[],{"trials":1449,"activeCount":94},[],{"trials":1451,"activeCount":94},[1452],{"nctId":1453,"briefTitle":1454,"status":693,"phases":1455,"primaryCompletion":1456,"completion":1456,"start":1457,"enrollment":1458,"conditions":1459,"interventions":1461},"NCT02809027","Efficacy of Ginger in the Prevention of Abdominal Distention in Post Cesarean Section Patient",[85],"2017-06-30","2016-06-01",178,[1460],"Post Cesarean Section Patient",[1440],{"trials":1463,"activeCount":94},[],{"intervention":1465,"totalTrials":90,"cells":1466},"FluvoxaMINE Maleate 50 MG",{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1473,"PHASE4":1475,"NA":1491},{"trials":1468,"activeCount":94},[],{"trials":1470,"activeCount":94},[],{"trials":1472,"activeCount":94},[],{"trials":1474,"activeCount":94},[],{"trials":1476,"activeCount":94},[1477],{"nctId":1478,"briefTitle":1479,"status":693,"phases":1480,"primaryCompletion":1481,"completion":1481,"start":1482,"enrollment":1483,"conditions":1484,"interventions":1486},"NCT05087381","Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community",[85],"2022-06-21","2021-10-01",1200,[1485],"Treatment Efficacy",[1465,1487,1488,1489,1490],"Fluvoxamine, Bromhexine","Fluvoxamine, Cyproheptadine","Niclosamide Pill","Niclosamide, Bromhexine",{"trials":1492,"activeCount":94},[],{"intervention":1487,"totalTrials":90,"cells":1494},{"EARLY_PHASE1":1495,"PHASE1":1497,"PHASE2":1499,"PHASE3":1501,"PHASE4":1503,"NA":1509},{"trials":1496,"activeCount":94},[],{"trials":1498,"activeCount":94},[],{"trials":1500,"activeCount":94},[],{"trials":1502,"activeCount":94},[],{"trials":1504,"activeCount":94},[1505],{"nctId":1478,"briefTitle":1479,"status":693,"phases":1506,"primaryCompletion":1481,"completion":1481,"start":1482,"enrollment":1483,"conditions":1507,"interventions":1508},[85],[1485],[1465,1487,1488,1489,1490],{"trials":1510,"activeCount":94},[],{"intervention":1488,"totalTrials":90,"cells":1512},{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1527},{"trials":1514,"activeCount":94},[],{"trials":1516,"activeCount":94},[],{"trials":1518,"activeCount":94},[],{"trials":1520,"activeCount":94},[],{"trials":1522,"activeCount":94},[1523],{"nctId":1478,"briefTitle":1479,"status":693,"phases":1524,"primaryCompletion":1481,"completion":1481,"start":1482,"enrollment":1483,"conditions":1525,"interventions":1526},[85],[1485],[1465,1487,1488,1489,1490],{"trials":1528,"activeCount":94},[],{"intervention":1489,"totalTrials":90,"cells":1530},{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1535,"PHASE3":1537,"PHASE4":1539,"NA":1545},{"trials":1532,"activeCount":94},[],{"trials":1534,"activeCount":94},[],{"trials":1536,"activeCount":94},[],{"trials":1538,"activeCount":94},[],{"trials":1540,"activeCount":94},[1541],{"nctId":1478,"briefTitle":1479,"status":693,"phases":1542,"primaryCompletion":1481,"completion":1481,"start":1482,"enrollment":1483,"conditions":1543,"interventions":1544},[85],[1485],[1465,1487,1488,1489,1490],{"trials":1546,"activeCount":94},[],{"intervention":1490,"totalTrials":90,"cells":1548},{"EARLY_PHASE1":1549,"PHASE1":1551,"PHASE2":1553,"PHASE3":1555,"PHASE4":1557,"NA":1563},{"trials":1550,"activeCount":94},[],{"trials":1552,"activeCount":94},[],{"trials":1554,"activeCount":94},[],{"trials":1556,"activeCount":94},[],{"trials":1558,"activeCount":94},[1559],{"nctId":1478,"briefTitle":1479,"status":693,"phases":1560,"primaryCompletion":1481,"completion":1481,"start":1482,"enrollment":1483,"conditions":1561,"interventions":1562},[85],[1485],[1465,1487,1488,1489,1490],{"trials":1564,"activeCount":94},[],{"intervention":1566,"totalTrials":90,"cells":1567},"Acetate-free dialysis solution",{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1574,"PHASE4":1576,"NA":1588},{"trials":1569,"activeCount":94},[],{"trials":1571,"activeCount":94},[],{"trials":1573,"activeCount":94},[],{"trials":1575,"activeCount":94},[],{"trials":1577,"activeCount":94},[1578],{"nctId":1579,"briefTitle":1580,"status":693,"phases":1581,"primaryCompletion":1582,"completion":1582,"start":1583,"enrollment":1584,"conditions":1585,"interventions":1587},"NCT01778283","Comparison of Cardiac Index and Cardiac Output Effect During Maintenance Hemodialysis Between Acetate-Free and Acetate-Based Online Hemodiafiltration",[85],"2012-11","2012-10",22,[1586],"End-stage Renal Disease",[1566],{"trials":1589,"activeCount":94},[],{"intervention":1591,"totalTrials":90,"cells":1592},"Alginate-based reflux suppressant",{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1597,"PHASE3":1599,"PHASE4":1601,"NA":1612},{"trials":1594,"activeCount":94},[],{"trials":1596,"activeCount":94},[],{"trials":1598,"activeCount":94},[],{"trials":1600,"activeCount":94},[],{"trials":1602,"activeCount":94},[1603],{"nctId":1604,"briefTitle":1605,"status":693,"phases":1606,"primaryCompletion":1607,"completion":1607,"start":1389,"enrollment":740,"conditions":1608,"interventions":1610},"NCT02470117","Alginate-based Reflux Suppressant and Magnesium-aluminium Antacid Gel for Treatment of Heartburn in Pregnancy",[85],"2016-07",[1609],"Heartburn in Pregnancy",[1591,1611],"magnesium-aluminium antacid gel",{"trials":1613,"activeCount":94},[],{"intervention":1611,"totalTrials":90,"cells":1615},{"EARLY_PHASE1":1616,"PHASE1":1618,"PHASE2":1620,"PHASE3":1622,"PHASE4":1624,"NA":1630},{"trials":1617,"activeCount":94},[],{"trials":1619,"activeCount":94},[],{"trials":1621,"activeCount":94},[],{"trials":1623,"activeCount":94},[],{"trials":1625,"activeCount":94},[1626],{"nctId":1604,"briefTitle":1605,"status":693,"phases":1627,"primaryCompletion":1607,"completion":1607,"start":1389,"enrollment":740,"conditions":1628,"interventions":1629},[85],[1609],[1591,1611],{"trials":1631,"activeCount":94},[],{"intervention":1633,"totalTrials":90,"cells":1634},"Moringa oleifera leaf",{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1639,"PHASE3":1641,"PHASE4":1643,"NA":1655},{"trials":1636,"activeCount":94},[],{"trials":1638,"activeCount":94},[],{"trials":1640,"activeCount":94},[],{"trials":1642,"activeCount":94},[],{"trials":1644,"activeCount":94},[1645],{"nctId":1646,"briefTitle":1647,"status":693,"phases":1648,"primaryCompletion":1649,"completion":1650,"start":1651,"enrollment":1652,"conditions":1653,"interventions":1654},"NCT04487613","Effect of Moringa Oleifera Capsule in Increasing Breast Milk Volume in Early Postpartum Patients",[85],"2022-05-31","2022-06-30","2021-03-15",88,[1213],[1633],{"trials":1656,"activeCount":94},[],{"intervention":757,"totalTrials":90,"cells":1658},{"EARLY_PHASE1":1659,"PHASE1":1661,"PHASE2":1663,"PHASE3":1665,"PHASE4":1667,"NA":1673},{"trials":1660,"activeCount":94},[],{"trials":1662,"activeCount":94},[],{"trials":1664,"activeCount":94},[],{"trials":1666,"activeCount":94},[],{"trials":1668,"activeCount":94},[1669],{"nctId":747,"briefTitle":748,"status":429,"phases":1670,"primaryCompletion":750,"completion":751,"start":752,"enrollment":753,"conditions":1671,"interventions":1672},[85],[755],[757,722],{"trials":1674,"activeCount":94},[],{"intervention":1676,"totalTrials":90,"cells":1677},"Sugammadex",{"EARLY_PHASE1":1678,"PHASE1":1680,"PHASE2":1682,"PHASE3":1684,"PHASE4":1686,"NA":1699},{"trials":1679,"activeCount":94},[],{"trials":1681,"activeCount":94},[],{"trials":1683,"activeCount":94},[],{"trials":1685,"activeCount":94},[],{"trials":1687,"activeCount":94},[1688],{"nctId":1689,"briefTitle":1690,"status":693,"phases":1691,"primaryCompletion":1692,"completion":1692,"start":1693,"enrollment":1694,"conditions":1695,"interventions":1697},"NCT02451202","Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures",[85],"2018-03","2016-06",102,[1696],"Laryngoscopic Surgical Procedures",[1676,1698],"Rocuronium",{"trials":1700,"activeCount":94},[],{"intervention":1698,"totalTrials":90,"cells":1702},{"EARLY_PHASE1":1703,"PHASE1":1705,"PHASE2":1707,"PHASE3":1709,"PHASE4":1711,"NA":1717},{"trials":1704,"activeCount":94},[],{"trials":1706,"activeCount":94},[],{"trials":1708,"activeCount":94},[],{"trials":1710,"activeCount":94},[],{"trials":1712,"activeCount":94},[1713],{"nctId":1689,"briefTitle":1690,"status":693,"phases":1714,"primaryCompletion":1692,"completion":1692,"start":1693,"enrollment":1694,"conditions":1715,"interventions":1716},[85],[1696],[1676,1698],{"trials":1718,"activeCount":94},[],{"intervention":1720,"totalTrials":90,"cells":1721},"Intravenous Rituximab",{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1726,"PHASE3":1728,"PHASE4":1730,"NA":1741},{"trials":1723,"activeCount":94},[],{"trials":1725,"activeCount":94},[],{"trials":1727,"activeCount":94},[],{"trials":1729,"activeCount":94},[],{"trials":1731,"activeCount":94},[1732],{"nctId":1733,"briefTitle":1734,"status":429,"phases":1735,"primaryCompletion":1388,"completion":1388,"start":1736,"enrollment":615,"conditions":1737,"interventions":1739},"NCT02571842","Rituximab in Recurrent IgA Nephropathy",[85],"2012-01",[1738],"Recurrent IgA Nephropathy",[1720,1740],"ACEI\u002FARB and corticosteroids",{"trials":1742,"activeCount":94},[],{"intervention":1740,"totalTrials":90,"cells":1744},{"EARLY_PHASE1":1745,"PHASE1":1747,"PHASE2":1749,"PHASE3":1751,"PHASE4":1753,"NA":1759},{"trials":1746,"activeCount":94},[],{"trials":1748,"activeCount":94},[],{"trials":1750,"activeCount":94},[],{"trials":1752,"activeCount":94},[],{"trials":1754,"activeCount":94},[1755],{"nctId":1733,"briefTitle":1734,"status":429,"phases":1756,"primaryCompletion":1388,"completion":1388,"start":1736,"enrollment":615,"conditions":1757,"interventions":1758},[85],[1738],[1720,1740],{"trials":1760,"activeCount":94},[],{"intervention":1762,"totalTrials":90,"cells":1763},"EE 20 microgram with desogestrel 150 mg",{"EARLY_PHASE1":1764,"PHASE1":1766,"PHASE2":1768,"PHASE3":1770,"PHASE4":1772,"NA":1785},{"trials":1765,"activeCount":94},[],{"trials":1767,"activeCount":94},[],{"trials":1769,"activeCount":94},[],{"trials":1771,"activeCount":94},[],{"trials":1773,"activeCount":94},[1774],{"nctId":1775,"briefTitle":1776,"status":693,"phases":1777,"primaryCompletion":1778,"completion":1779,"start":1780,"enrollment":753,"conditions":1781,"interventions":1783},"NCT01482338","Premenstrual Symptoms Treatment Comparing Between Oral Contraceptives Containing Desogestrel and Drospirenone",[85],"2012-02","2012-03","2011-06",[1782],"Premenstrual Syndrome",[1762,1784],"EE 20 microgram with drospirenone 3 mg",{"trials":1786,"activeCount":94},[],{"intervention":1784,"totalTrials":90,"cells":1788},{"EARLY_PHASE1":1789,"PHASE1":1791,"PHASE2":1793,"PHASE3":1795,"PHASE4":1797,"NA":1803},{"trials":1790,"activeCount":94},[],{"trials":1792,"activeCount":94},[],{"trials":1794,"activeCount":94},[],{"trials":1796,"activeCount":94},[],{"trials":1798,"activeCount":94},[1799],{"nctId":1775,"briefTitle":1776,"status":693,"phases":1800,"primaryCompletion":1778,"completion":1779,"start":1780,"enrollment":753,"conditions":1801,"interventions":1802},[85],[1782],[1762,1784],{"trials":1804,"activeCount":94},[],{"intervention":1806,"totalTrials":90,"cells":1807},"0.05% cyclosporin eye drop",{"EARLY_PHASE1":1808,"PHASE1":1810,"PHASE2":1812,"PHASE3":1814,"PHASE4":1816,"NA":1827},{"trials":1809,"activeCount":94},[],{"trials":1811,"activeCount":94},[],{"trials":1813,"activeCount":94},[],{"trials":1815,"activeCount":94},[],{"trials":1817,"activeCount":94},[1818],{"nctId":1819,"briefTitle":1820,"status":429,"phases":1821,"primaryCompletion":1068,"completion":1822,"start":1823,"enrollment":887,"conditions":1824,"interventions":1826},"NCT00704275","Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes",[85],"2008-10","2007-06",[1825],"Dry Eye",[1806],{"trials":1828,"activeCount":94},[],{"intervention":1830,"totalTrials":90,"cells":1831},"Estrogen patch",{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1836,"PHASE3":1838,"PHASE4":1848,"NA":1850},{"trials":1833,"activeCount":94},[],{"trials":1835,"activeCount":94},[],{"trials":1837,"activeCount":94},[],{"trials":1839,"activeCount":94},[1840],{"nctId":1841,"briefTitle":1842,"status":693,"phases":1843,"primaryCompletion":1736,"completion":1736,"start":1844,"enrollment":259,"conditions":1845,"interventions":1847},"NCT01501422","Effect of Estrogen Therapy on Objective Sleep Quality in Postmenopausal Women",[84],"2011-07",[1846],"Insomniac Postmenopausal Women",[1830],{"trials":1849,"activeCount":94},[],{"trials":1851,"activeCount":94},[],{"intervention":1853,"totalTrials":90,"cells":1854},"Standard treatment",{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1861,"PHASE4":1873,"NA":1875},{"trials":1856,"activeCount":94},[],{"trials":1858,"activeCount":94},[],{"trials":1860,"activeCount":94},[],{"trials":1862,"activeCount":94},[1863],{"nctId":1864,"briefTitle":1865,"status":693,"phases":1866,"primaryCompletion":1867,"completion":1867,"start":1868,"enrollment":1869,"conditions":1870,"interventions":1872},"NCT03518398","Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction",[84],"2019-04-02","2018-07-03",114,[1871,1367],"Meibomian Gland Dysfunction (Disorder)",[1853],{"trials":1874,"activeCount":94},[],{"trials":1876,"activeCount":94},[],{"intervention":1878,"totalTrials":90,"cells":1879},"bevacizumab eye drop 0.05%",{"EARLY_PHASE1":1880,"PHASE1":1882,"PHASE2":1884,"PHASE3":1886,"PHASE4":1902,"NA":1904},{"trials":1881,"activeCount":94},[],{"trials":1883,"activeCount":94},[],{"trials":1885,"activeCount":94},[],{"trials":1887,"activeCount":94},[1888],{"nctId":1889,"briefTitle":1890,"status":693,"phases":1891,"primaryCompletion":1892,"completion":1893,"start":1894,"enrollment":777,"conditions":1895,"interventions":1900},"NCT01311960","Topical Bevacizumab for Preventing Recurrent Pterygium",[84],"2013-03","2013-04","2010-12",[1896,1897,1898,1899],"Pterygium","Bevacizumab","VEGF","Anti-VEGF",[1878,1901],"normal saline 0.9%",{"trials":1903,"activeCount":94},[],{"trials":1905,"activeCount":94},[],{"intervention":1901,"totalTrials":90,"cells":1907},{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1912,"PHASE3":1914,"PHASE4":1920,"NA":1922},{"trials":1909,"activeCount":94},[],{"trials":1911,"activeCount":94},[],{"trials":1913,"activeCount":94},[],{"trials":1915,"activeCount":94},[1916],{"nctId":1889,"briefTitle":1890,"status":693,"phases":1917,"primaryCompletion":1892,"completion":1893,"start":1894,"enrollment":777,"conditions":1918,"interventions":1919},[84],[1896,1897,1898,1899],[1878,1901],{"trials":1921,"activeCount":94},[],{"trials":1923,"activeCount":94},[],{"intervention":1925,"totalTrials":90,"cells":1926},"Gabapentin 300mg",{"EARLY_PHASE1":1927,"PHASE1":1929,"PHASE2":1931,"PHASE3":1933,"PHASE4":1945,"NA":1947},{"trials":1928,"activeCount":94},[],{"trials":1930,"activeCount":94},[],{"trials":1932,"activeCount":94},[],{"trials":1934,"activeCount":94},[1935],{"nctId":1936,"briefTitle":1937,"status":693,"phases":1938,"primaryCompletion":1939,"completion":1939,"start":1736,"enrollment":1940,"conditions":1941,"interventions":1944},"NCT03274167","Efficacy of Gabapentin in Alcohol Dependency Treatment",[84],"2014-12",112,[1942,1943],"Alcohol Drinking","Heavy Drinking",[1925],{"trials":1946,"activeCount":94},[],{"trials":1948,"activeCount":94},[],{"intervention":1950,"totalTrials":90,"cells":1951},"Essential oil",{"EARLY_PHASE1":1952,"PHASE1":1954,"PHASE2":1956,"PHASE3":1958,"PHASE4":1971,"NA":1973},{"trials":1953,"activeCount":94},[],{"trials":1955,"activeCount":94},[],{"trials":1957,"activeCount":94},[],{"trials":1959,"activeCount":94},[1960],{"nctId":1961,"briefTitle":1962,"status":693,"phases":1963,"primaryCompletion":1964,"completion":1964,"start":1965,"enrollment":1966,"conditions":1967,"interventions":1969},"NCT03296943","Efficacy of Inhalation of Essential Oil on the Reduction of Inhalants Craving",[84],"2010-11-30","2010-07-01",34,[1968],"Inhalants Craving",[1950,1970],"Perfume",{"trials":1972,"activeCount":94},[],{"trials":1974,"activeCount":94},[],{"intervention":1970,"totalTrials":90,"cells":1976},{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1981,"PHASE3":1983,"PHASE4":1989,"NA":1991},{"trials":1978,"activeCount":94},[],{"trials":1980,"activeCount":94},[],{"trials":1982,"activeCount":94},[],{"trials":1984,"activeCount":94},[1985],{"nctId":1961,"briefTitle":1962,"status":693,"phases":1986,"primaryCompletion":1964,"completion":1964,"start":1965,"enrollment":1966,"conditions":1987,"interventions":1988},[84],[1968],[1950,1970],{"trials":1990,"activeCount":94},[],{"trials":1992,"activeCount":94},[],{"intervention":701,"totalTrials":90,"cells":1994},{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2001,"PHASE4":2007,"NA":2009},{"trials":1996,"activeCount":94},[],{"trials":1998,"activeCount":94},[],{"trials":2000,"activeCount":94},[],{"trials":2002,"activeCount":94},[2003],{"nctId":691,"briefTitle":692,"status":693,"phases":2004,"primaryCompletion":695,"completion":696,"start":697,"enrollment":698,"conditions":2005,"interventions":2006},[84],[26,28,18],[680,701],{"trials":2008,"activeCount":94},[],{"trials":2010,"activeCount":94},[],{"intervention":2012,"totalTrials":90,"cells":2013},"0.9% NaCl solution",{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2018,"PHASE3":2020,"PHASE4":2032,"NA":2034},{"trials":2015,"activeCount":94},[],{"trials":2017,"activeCount":94},[],{"trials":2019,"activeCount":94},[],{"trials":2021,"activeCount":94},[2022],{"nctId":2023,"briefTitle":2024,"status":785,"phases":2025,"primaryCompletion":2026,"completion":2026,"start":2027,"enrollment":2028,"conditions":2029,"interventions":2031},"NCT02003794","Randomized Controlled Study of the Effectiveness of IV Fluid Infusion in Patients With Acute Ischemic Stroke (IVIS)",[84],"2015-01","2013-05",120,[2030],"Ischemic Stroke",[2012],{"trials":2033,"activeCount":94},[],{"trials":2035,"activeCount":94},[],{"intervention":2037,"totalTrials":90,"cells":2038},"Ketosteril",{"EARLY_PHASE1":2039,"PHASE1":2041,"PHASE2":2043,"PHASE3":2045,"PHASE4":2057,"NA":2059},{"trials":2040,"activeCount":94},[],{"trials":2042,"activeCount":94},[],{"trials":2044,"activeCount":94},[],{"trials":2046,"activeCount":94},[2047],{"nctId":2048,"briefTitle":2049,"status":429,"phases":2050,"primaryCompletion":2051,"completion":2052,"start":2053,"enrollment":470,"conditions":2054,"interventions":2056},"NCT05030168","Effects of Low Protein Diet Supplemented With Ketoanalogues on Preservation of Kidney Function in Incremental Dialysis",[83,84],"2023-12","2024-03","2021-12",[2055,30],"Kidney Function",[2037],{"trials":2058,"activeCount":94},[],{"trials":2060,"activeCount":94},[],{"intervention":2062,"totalTrials":90,"cells":2063},"mycophenolate sodium",{"EARLY_PHASE1":2064,"PHASE1":2066,"PHASE2":2068,"PHASE3":2070,"PHASE4":2082,"NA":2084},{"trials":2065,"activeCount":94},[],{"trials":2067,"activeCount":94},[],{"trials":2069,"activeCount":94},[],{"trials":2071,"activeCount":94},[2072],{"nctId":2073,"briefTitle":2074,"status":785,"phases":2075,"primaryCompletion":2076,"completion":2076,"start":2077,"enrollment":2078,"conditions":2079,"interventions":2080},"NCT01015456","The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis",[84],"2013-01","2010-01",59,[32],[2062,2081],"cyclophosphamide",{"trials":2083,"activeCount":94},[],{"trials":2085,"activeCount":94},[],{"intervention":2081,"totalTrials":90,"cells":2087},{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2094,"PHASE4":2100,"NA":2102},{"trials":2089,"activeCount":94},[],{"trials":2091,"activeCount":94},[],{"trials":2093,"activeCount":94},[],{"trials":2095,"activeCount":94},[2096],{"nctId":2073,"briefTitle":2074,"status":785,"phases":2097,"primaryCompletion":2076,"completion":2076,"start":2077,"enrollment":2078,"conditions":2098,"interventions":2099},[84],[32],[2062,2081],{"trials":2101,"activeCount":94},[],{"trials":2103,"activeCount":94},[],{"intervention":2105,"totalTrials":90,"cells":2106},"denture adhesive",{"EARLY_PHASE1":2107,"PHASE1":2109,"PHASE2":2111,"PHASE3":2113,"PHASE4":2126,"NA":2128},{"trials":2108,"activeCount":94},[],{"trials":2110,"activeCount":94},[],{"trials":2112,"activeCount":94},[],{"trials":2114,"activeCount":94},[2115],{"nctId":2116,"briefTitle":2117,"status":693,"phases":2118,"primaryCompletion":2119,"completion":2120,"start":2121,"enrollment":932,"conditions":2122,"interventions":2125},"NCT04942262","Oral Health-related Quality of Life and Masticatory Function After Using Denture Adhesive and Denture Liner",[84],"2020-01-17","2020-04-30","2019-01-31",[2123,2124],"Complete Denture","Complete Edentulism",[2105],{"trials":2127,"activeCount":94},[],{"trials":2129,"activeCount":94},[],{"intervention":2131,"totalTrials":90,"cells":2132},"Epidermal growth factor with silver sulfadiazine cream",{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2137,"PHASE3":2139,"PHASE4":2150,"NA":2152},{"trials":2134,"activeCount":94},[],{"trials":2136,"activeCount":94},[],{"trials":2138,"activeCount":94},[],{"trials":2140,"activeCount":94},[2141],{"nctId":2142,"briefTitle":2143,"status":693,"phases":2144,"primaryCompletion":2145,"completion":2145,"start":775,"enrollment":1966,"conditions":2146,"interventions":2148},"NCT01553708","Effect of EGF With Silver Sulfadiazine Cream Compared With Silver Zinc Sulfadiazine Cream for Treatment of Burn Wound",[83,84],"2012-05",[2147],"Deep Partial Thickness Burn",[2131,2149],"Silver zinc sulfadiazine cream",{"trials":2151,"activeCount":94},[],{"trials":2153,"activeCount":94},[],{"intervention":2149,"totalTrials":90,"cells":2155},{"EARLY_PHASE1":2156,"PHASE1":2158,"PHASE2":2160,"PHASE3":2162,"PHASE4":2168,"NA":2170},{"trials":2157,"activeCount":94},[],{"trials":2159,"activeCount":94},[],{"trials":2161,"activeCount":94},[],{"trials":2163,"activeCount":94},[2164],{"nctId":2142,"briefTitle":2143,"status":693,"phases":2165,"primaryCompletion":2145,"completion":2145,"start":775,"enrollment":1966,"conditions":2166,"interventions":2167},[83,84],[2147],[2131,2149],{"trials":2169,"activeCount":94},[],{"trials":2171,"activeCount":94},[],{"intervention":2173,"totalTrials":90,"cells":2174},"\"Emicizumab\", \"HEMLIBRA®\"",{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2181,"PHASE4":2193,"NA":2195},{"trials":2176,"activeCount":94},[],{"trials":2178,"activeCount":94},[],{"trials":2180,"activeCount":94},[],{"trials":2182,"activeCount":94},[2183],{"nctId":2184,"briefTitle":2185,"status":429,"phases":2186,"primaryCompletion":2187,"completion":2188,"start":2189,"enrollment":1237,"conditions":2190,"interventions":2192},"NCT06155955","Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A",[83,84],"2024-03-21","2024-06-21","2023-06-22",[1239,2191],"Joint Bleed",[2173],{"trials":2194,"activeCount":94},[],{"trials":2196,"activeCount":94},[],{"intervention":2198,"totalTrials":90,"cells":2199},"Cyclosporine combine with mycophenolate mofetil",{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2204,"PHASE3":2206,"PHASE4":2218,"NA":2220},{"trials":2201,"activeCount":94},[],{"trials":2203,"activeCount":94},[],{"trials":2205,"activeCount":94},[],{"trials":2207,"activeCount":94},[2208],{"nctId":2209,"briefTitle":2210,"status":785,"phases":2211,"primaryCompletion":1736,"completion":1736,"start":2212,"enrollment":2213,"conditions":2214,"interventions":2216},"NCT01288131","Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment",[84],"2009-01",8,[2215],"Anti-r-HuEpo Associated PRCA Subjects",[2198,2217],"Cyclophosphamide + pred",{"trials":2219,"activeCount":94},[],{"trials":2221,"activeCount":94},[],{"intervention":2217,"totalTrials":90,"cells":2223},{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2228,"PHASE3":2230,"PHASE4":2236,"NA":2238},{"trials":2225,"activeCount":94},[],{"trials":2227,"activeCount":94},[],{"trials":2229,"activeCount":94},[],{"trials":2231,"activeCount":94},[2232],{"nctId":2209,"briefTitle":2210,"status":785,"phases":2233,"primaryCompletion":1736,"completion":1736,"start":2212,"enrollment":2213,"conditions":2234,"interventions":2235},[84],[2215],[2198,2217],{"trials":2237,"activeCount":94},[],{"trials":2239,"activeCount":94},[],{"intervention":2241,"totalTrials":90,"cells":2242},"Tinospora Crispa-extract Product",{"EARLY_PHASE1":2243,"PHASE1":2245,"PHASE2":2247,"PHASE3":2249,"PHASE4":2263,"NA":2265},{"trials":2244,"activeCount":94},[],{"trials":2246,"activeCount":94},[],{"trials":2248,"activeCount":94},[],{"trials":2250,"activeCount":94},[2251],{"nctId":2252,"briefTitle":2253,"status":693,"phases":2254,"primaryCompletion":1939,"completion":1939,"start":2255,"enrollment":2256,"conditions":2257,"interventions":2261},"NCT01958866","Study of Efficacy and Safety of Tinospora Crispa-extract Product Compared With the Acetaminophen",[83,84],"2013-10",96,[2258,2259,2260],"Patients With Body Temperature Between 37.8-38.5","No Sign of Infection","No Liver and Kidney Problem",[2241,2262],"Acetaminophen",{"trials":2264,"activeCount":94},[],{"trials":2266,"activeCount":94},[],{"intervention":2262,"totalTrials":90,"cells":2268},{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2273,"PHASE3":2275,"PHASE4":2281,"NA":2283},{"trials":2270,"activeCount":94},[],{"trials":2272,"activeCount":94},[],{"trials":2274,"activeCount":94},[],{"trials":2276,"activeCount":94},[2277],{"nctId":2252,"briefTitle":2253,"status":693,"phases":2278,"primaryCompletion":1939,"completion":1939,"start":2255,"enrollment":2256,"conditions":2279,"interventions":2280},[83,84],[2258,2259,2260],[2241,2262],{"trials":2282,"activeCount":94},[],{"trials":2284,"activeCount":94},[],{"intervention":2286,"totalTrials":90,"cells":2287},"ECa 233",{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2294,"PHASE4":2308,"NA":2310},{"trials":2289,"activeCount":94},[],{"trials":2291,"activeCount":94},[],{"trials":2293,"activeCount":94},[],{"trials":2295,"activeCount":94},[2296],{"nctId":2297,"briefTitle":2298,"status":693,"phases":2299,"primaryCompletion":2300,"completion":2301,"start":2302,"enrollment":2303,"conditions":2304,"interventions":2306},"NCT06231212","Efficacy of a Standardized Centella Asiatica Extract in Patients With Temporomandibular Disorder",[83,84],"2021-09-01","2022-12-30","2020-08-05",23,[2305],"Temporomandibular Disorder",[2286,2307],"Ibuprofen",{"trials":2309,"activeCount":94},[],{"trials":2311,"activeCount":94},[],{"intervention":2307,"totalTrials":90,"cells":2313},{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2318,"PHASE3":2320,"PHASE4":2326,"NA":2328},{"trials":2315,"activeCount":94},[],{"trials":2317,"activeCount":94},[],{"trials":2319,"activeCount":94},[],{"trials":2321,"activeCount":94},[2322],{"nctId":2297,"briefTitle":2298,"status":693,"phases":2323,"primaryCompletion":2300,"completion":2301,"start":2302,"enrollment":2303,"conditions":2324,"interventions":2325},[83,84],[2305],[2286,2307],{"trials":2327,"activeCount":94},[],{"trials":2329,"activeCount":94},[],{"intervention":2331,"totalTrials":90,"cells":2332},"Intravenous iron",{"EARLY_PHASE1":2333,"PHASE1":2335,"PHASE2":2337,"PHASE3":2339,"PHASE4":2349,"NA":2351},{"trials":2334,"activeCount":94},[],{"trials":2336,"activeCount":94},[],{"trials":2338,"activeCount":94},[],{"trials":2340,"activeCount":94},[2341],{"nctId":2342,"briefTitle":2343,"status":693,"phases":2344,"primaryCompletion":1583,"completion":1582,"start":1780,"enrollment":2345,"conditions":2346,"interventions":2348},"NCT01435200","Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy",[84],64,[2347],"Gynecologic Cancer",[2331],{"trials":2350,"activeCount":94},[],{"trials":2352,"activeCount":94},[],{"intervention":2354,"totalTrials":90,"cells":2355},"neomycin sulfate, polymyxin B sulfate and gramicidin",{"EARLY_PHASE1":2356,"PHASE1":2358,"PHASE2":2360,"PHASE3":2362,"PHASE4":2374,"NA":2376},{"trials":2357,"activeCount":94},[],{"trials":2359,"activeCount":94},[],{"trials":2361,"activeCount":94},[],{"trials":2363,"activeCount":94},[2364],{"nctId":2365,"briefTitle":2366,"status":429,"phases":2367,"completion":2368,"start":2369,"enrollment":2028,"conditions":2370,"interventions":2372},"NCT00534391","Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage",[84],"2008-12","2007-09",[2371],"Hordeolum",[2354,2373],"Artificial tear",{"trials":2375,"activeCount":94},[],{"trials":2377,"activeCount":94},[],{"intervention":2373,"totalTrials":90,"cells":2379},{"EARLY_PHASE1":2380,"PHASE1":2382,"PHASE2":2384,"PHASE3":2386,"PHASE4":2392,"NA":2394},{"trials":2381,"activeCount":94},[],{"trials":2383,"activeCount":94},[],{"trials":2385,"activeCount":94},[],{"trials":2387,"activeCount":94},[2388],{"nctId":2365,"briefTitle":2366,"status":429,"phases":2389,"completion":2368,"start":2369,"enrollment":2028,"conditions":2390,"interventions":2391},[84],[2371],[2354,2373],{"trials":2393,"activeCount":94},[],{"trials":2395,"activeCount":94},[],{"intervention":2397,"totalTrials":90,"cells":2398},"2% ketoconazole cream",{"EARLY_PHASE1":2399,"PHASE1":2401,"PHASE2":2403,"PHASE3":2405,"PHASE4":2419,"NA":2421},{"trials":2400,"activeCount":94},[],{"trials":2402,"activeCount":94},[],{"trials":2404,"activeCount":94},[],{"trials":2406,"activeCount":94},[2407],{"nctId":2408,"briefTitle":2409,"status":693,"phases":2410,"primaryCompletion":2411,"completion":2412,"start":2413,"enrollment":2414,"conditions":2415,"interventions":2417},"NCT03178994","The Study of Efficacy and Safety of 2% Ketoconazole Cream in Thai Females With Mild Degree of Post - Adolescence Acne",[84],"2018-09-15","2018-12-30","2017-08-01",42,[2416],"Post - Adolescence Acne",[2397,2418],"Hydrophilic Cream",{"trials":2420,"activeCount":94},[],{"trials":2422,"activeCount":94},[],{"intervention":2418,"totalTrials":90,"cells":2424},{"EARLY_PHASE1":2425,"PHASE1":2427,"PHASE2":2429,"PHASE3":2431,"PHASE4":2437,"NA":2439},{"trials":2426,"activeCount":94},[],{"trials":2428,"activeCount":94},[],{"trials":2430,"activeCount":94},[],{"trials":2432,"activeCount":94},[2433],{"nctId":2408,"briefTitle":2409,"status":693,"phases":2434,"primaryCompletion":2411,"completion":2412,"start":2413,"enrollment":2414,"conditions":2435,"interventions":2436},[84],[2416],[2397,2418],{"trials":2438,"activeCount":94},[],{"trials":2440,"activeCount":94},[],{"intervention":2442,"totalTrials":90,"cells":2443},"Phlai",{"EARLY_PHASE1":2444,"PHASE1":2446,"PHASE2":2448,"PHASE3":2450,"PHASE4":2461,"NA":2463},{"trials":2445,"activeCount":94},[],{"trials":2447,"activeCount":94},[],{"trials":2449,"activeCount":94},[],{"trials":2451,"activeCount":94},[2452],{"nctId":2453,"briefTitle":2454,"status":693,"phases":2455,"primaryCompletion":2456,"completion":2456,"start":2457,"enrollment":2458,"conditions":2459,"interventions":2460},"NCT04182919","\"Efficacy and Safety of Phlai Capsule Compared to Placebo as the Treatment in Allergic Rhinitis Patients\"",[84],"2021-12-20","2020-01-31",267,[15],[2442],{"trials":2462,"activeCount":94},[],{"trials":2464,"activeCount":94},[],{"intervention":2466,"totalTrials":90,"cells":2467},"ChulaCov19 vaccine",{"EARLY_PHASE1":2468,"PHASE1":2470,"PHASE2":2472,"PHASE3":2485,"PHASE4":2487,"NA":2489},{"trials":2469,"activeCount":94},[],{"trials":2471,"activeCount":94},[],{"trials":2473,"activeCount":94},[2474],{"nctId":2475,"briefTitle":2476,"status":693,"phases":2477,"primaryCompletion":2478,"completion":2479,"start":2480,"enrollment":2481,"conditions":2482,"interventions":2484},"NCT04566276","ChulaCov19 Vaccine in Healthy Adults",[82,83],"2022-10-01","2022-12-06","2021-05-03",192,[2483,21],"COVID-19 Vaccine",[2466],{"trials":2486,"activeCount":94},[],{"trials":2488,"activeCount":94},[],{"trials":2490,"activeCount":94},[],{"intervention":2492,"totalTrials":90,"cells":2493},"Desloratadine plus cilostazol and dipyridamole",{"EARLY_PHASE1":2494,"PHASE1":2496,"PHASE2":2498,"PHASE3":2511,"PHASE4":2513,"NA":2515},{"trials":2495,"activeCount":94},[],{"trials":2497,"activeCount":94},[],{"trials":2499,"activeCount":94},[2500],{"nctId":2501,"briefTitle":2502,"status":429,"phases":2503,"primaryCompletion":354,"completion":2504,"start":2505,"enrollment":2506,"conditions":2507,"interventions":2509},"NCT06268470","Antiplatelet Therapy in Chronic Urticaria",[83],"2024-05-01","2018-06-01",12,[2508],"Chronic Urticaria",[2492,2510],"Desloratadine",{"trials":2512,"activeCount":94},[],{"trials":2514,"activeCount":94},[],{"trials":2516,"activeCount":94},[],{"intervention":2510,"totalTrials":90,"cells":2518},{"EARLY_PHASE1":2519,"PHASE1":2521,"PHASE2":2523,"PHASE3":2529,"PHASE4":2531,"NA":2533},{"trials":2520,"activeCount":94},[],{"trials":2522,"activeCount":94},[],{"trials":2524,"activeCount":94},[2525],{"nctId":2501,"briefTitle":2502,"status":429,"phases":2526,"primaryCompletion":354,"completion":2504,"start":2505,"enrollment":2506,"conditions":2527,"interventions":2528},[83],[2508],[2492,2510],{"trials":2530,"activeCount":94},[],{"trials":2532,"activeCount":94},[],{"trials":2534,"activeCount":94},[],{"intervention":2536,"totalTrials":90,"cells":2537},"Depot medroxyprogesterone acetate",{"EARLY_PHASE1":2538,"PHASE1":2540,"PHASE2":2542,"PHASE3":2552,"PHASE4":2554,"NA":2556},{"trials":2539,"activeCount":94},[],{"trials":2541,"activeCount":94},[],{"trials":2543,"activeCount":94},[2544],{"nctId":2545,"briefTitle":2546,"status":693,"phases":2547,"primaryCompletion":2548,"completion":2548,"start":837,"enrollment":470,"conditions":2549,"interventions":2551},"NCT02894151","Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients",[83],"2016-05",[2550],"Clinically Diagnosed Endometriotic Patient Was Defined as a Woman Who Has Pelvic Pain and at Least One Evidence of PV or TVS",[2536],{"trials":2553,"activeCount":94},[],{"trials":2555,"activeCount":94},[],{"trials":2557,"activeCount":94},[],{"intervention":2559,"totalTrials":90,"cells":2560},"Lime Powder Regimen",{"EARLY_PHASE1":2561,"PHASE1":2563,"PHASE2":2565,"PHASE3":2577,"PHASE4":2579,"NA":2581},{"trials":2562,"activeCount":94},[],{"trials":2564,"activeCount":94},[],{"trials":2566,"activeCount":94},[2567],{"nctId":2568,"briefTitle":2569,"status":693,"phases":2570,"primaryCompletion":2505,"completion":2571,"start":2572,"enrollment":2573,"conditions":2574,"interventions":2576},"NCT03258190","Lime Powder Regimen (LPR) for Prevention of Renal Stone Recurrence",[83],"2018-06-30","2014-07-01",137,[2575],"Urolithiasis",[2559],{"trials":2578,"activeCount":94},[],{"trials":2580,"activeCount":94},[],{"trials":2582,"activeCount":94},[],{"intervention":2584,"totalTrials":90,"cells":2585},"Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1",{"EARLY_PHASE1":2586,"PHASE1":2588,"PHASE2":2590,"PHASE3":2602,"PHASE4":2604,"NA":2606},{"trials":2587,"activeCount":94},[],{"trials":2589,"activeCount":94},[],{"trials":2591,"activeCount":94},[2592],{"nctId":2593,"briefTitle":2594,"status":693,"phases":2595,"primaryCompletion":2596,"completion":51,"start":2597,"enrollment":16,"conditions":2598,"interventions":2600},"NCT05763329","Effects of Lemborexant as a Treatment for Moderate-to-severe OSA Patients With Low Arousal Threshold",[82,83],"2025-02-28","2023-02-01",[2599],"OSA",[2584,2601],"Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2",{"trials":2603,"activeCount":94},[],{"trials":2605,"activeCount":94},[],{"trials":2607,"activeCount":94},[],{"intervention":2601,"totalTrials":90,"cells":2609},{"EARLY_PHASE1":2610,"PHASE1":2612,"PHASE2":2614,"PHASE3":2620,"PHASE4":2622,"NA":2624},{"trials":2611,"activeCount":94},[],{"trials":2613,"activeCount":94},[],{"trials":2615,"activeCount":94},[2616],{"nctId":2593,"briefTitle":2594,"status":693,"phases":2617,"primaryCompletion":2596,"completion":51,"start":2597,"enrollment":16,"conditions":2618,"interventions":2619},[82,83],[2599],[2584,2601],{"trials":2621,"activeCount":94},[],{"trials":2623,"activeCount":94},[],{"trials":2625,"activeCount":94},[],{"intervention":2627,"totalTrials":90,"cells":2628},"1% xylocaine",{"EARLY_PHASE1":2629,"PHASE1":2631,"PHASE2":2633,"PHASE3":2644,"PHASE4":2646,"NA":2648},{"trials":2630,"activeCount":94},[],{"trials":2632,"activeCount":94},[],{"trials":2634,"activeCount":94},[2635],{"nctId":2636,"briefTitle":2637,"status":693,"phases":2638,"primaryCompletion":2368,"completion":776,"start":2639,"enrollment":94,"conditions":2640,"interventions":2643},"NCT00732589","SSNB in Hemiplegic Shoulder Pain",[83],"2008-08",[2641,2642],"Shoulder Pain","Stroke",[2627],{"trials":2645,"activeCount":94},[],{"trials":2647,"activeCount":94},[],{"trials":2649,"activeCount":94},[],{"intervention":2651,"totalTrials":90,"cells":2652},"DTG DT 20 mg",{"EARLY_PHASE1":2653,"PHASE1":2655,"PHASE2":2657,"PHASE3":2669,"PHASE4":2671,"NA":2673},{"trials":2654,"activeCount":94},[],{"trials":2656,"activeCount":94},[],{"trials":2658,"activeCount":94},[2659],{"nctId":2660,"briefTitle":2661,"status":429,"phases":2662,"primaryCompletion":2663,"completion":1650,"start":2664,"enrollment":615,"conditions":2665,"interventions":2667},"NCT05006170","Pharmacokinetics, Safety, and Efficacy of Dolutegravir Dispersible Tablets in Young Children Living With HIV",[83],"2022-02-28","2021-08-03",[2666],"Pediatric HIV Infection",[2651,2668],"DTG DT 25 mg",{"trials":2670,"activeCount":94},[],{"trials":2672,"activeCount":94},[],{"trials":2674,"activeCount":94},[],{"intervention":2668,"totalTrials":90,"cells":2676},{"EARLY_PHASE1":2677,"PHASE1":2679,"PHASE2":2681,"PHASE3":2687,"PHASE4":2689,"NA":2691},{"trials":2678,"activeCount":94},[],{"trials":2680,"activeCount":94},[],{"trials":2682,"activeCount":94},[2683],{"nctId":2660,"briefTitle":2661,"status":429,"phases":2684,"primaryCompletion":2663,"completion":1650,"start":2664,"enrollment":615,"conditions":2685,"interventions":2686},[83],[2666],[2651,2668],{"trials":2688,"activeCount":94},[],{"trials":2690,"activeCount":94},[],{"trials":2692,"activeCount":94},[],{"intervention":2694,"totalTrials":90,"cells":2695},"Comvigen",{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2700,"PHASE3":2718,"PHASE4":2720,"NA":2722},{"trials":2697,"activeCount":94},[],{"trials":2699,"activeCount":94},[],{"trials":2701,"activeCount":94},[2702],{"nctId":2703,"briefTitle":2704,"status":429,"phases":2705,"primaryCompletion":2706,"completion":2706,"start":2707,"enrollment":2708,"conditions":2709,"interventions":2716},"NCT05930730","Immunogenicity and Safety of Comvigen (Bivalent) Vaccine",[83],"2024-02","2023-10-09",450,[2710,2711,2712,2713,2714,2715],"Safety of a Single Dose of COMVIGEN Vaccine","Reactogenicity of a Single Dose of COMVIGEN Vaccine","Immunogenicity of a Single Dose of COMVIGEN Vaccine","Safety of a Single Dose of BIVALENT Pfizer\u002FBNT Vaccine","Reactogenicity of a Single Dose of BIVALENT Pfizer\u002FBNT Vaccine","Immunogenicity of a Single Dose of BIVALENT Pfizer\u002FBNT Vaccine",[2694,2717],"BIVALENT Pfizer\u002FBNT vaccine",{"trials":2719,"activeCount":94},[],{"trials":2721,"activeCount":94},[],{"trials":2723,"activeCount":94},[],{"intervention":2717,"totalTrials":90,"cells":2725},{"EARLY_PHASE1":2726,"PHASE1":2728,"PHASE2":2730,"PHASE3":2736,"PHASE4":2738,"NA":2740},{"trials":2727,"activeCount":94},[],{"trials":2729,"activeCount":94},[],{"trials":2731,"activeCount":94},[2732],{"nctId":2703,"briefTitle":2704,"status":429,"phases":2733,"primaryCompletion":2706,"completion":2706,"start":2707,"enrollment":2708,"conditions":2734,"interventions":2735},[83],[2710,2711,2712,2713,2714,2715],[2694,2717],{"trials":2737,"activeCount":94},[],{"trials":2739,"activeCount":94},[],{"trials":2741,"activeCount":94},[],{"intervention":2743,"totalTrials":90,"cells":2744},"Testosterone undecanoate",{"EARLY_PHASE1":2745,"PHASE1":2747,"PHASE2":2749,"PHASE3":2759,"PHASE4":2761,"NA":2763},{"trials":2746,"activeCount":94},[],{"trials":2748,"activeCount":94},[],{"trials":2750,"activeCount":94},[2751],{"nctId":2752,"briefTitle":2753,"status":693,"phases":2754,"primaryCompletion":1893,"completion":2027,"start":2755,"enrollment":1211,"conditions":2756,"interventions":2758},"NCT01724658","Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women",[83],"2012-06",[2757],"Female Sexual Dysfunction",[2743],{"trials":2760,"activeCount":94},[],{"trials":2762,"activeCount":94},[],{"trials":2764,"activeCount":94},[],{"intervention":2766,"totalTrials":90,"cells":2767},"Cyclofem",{"EARLY_PHASE1":2768,"PHASE1":2770,"PHASE2":2772,"PHASE3":2783,"PHASE4":2785,"NA":2787},{"trials":2769,"activeCount":94},[],{"trials":2771,"activeCount":94},[],{"trials":2773,"activeCount":94},[2774],{"nctId":2775,"briefTitle":2776,"status":429,"phases":2777,"primaryCompletion":860,"completion":860,"start":2778,"enrollment":2779,"conditions":2780,"interventions":2782},"NCT03264781","The Effect of Cyclofem® for the Treatment of Irregular Uterine Bleeding in Implant Contraceptive Users",[82,83],"2016-08",44,[2781],"Uterine Bleeding",[2766],{"trials":2784,"activeCount":94},[],{"trials":2786,"activeCount":94},[],{"trials":2788,"activeCount":94},[],{"intervention":2790,"totalTrials":90,"cells":2791},"Yttrium 90 -labeled ibritumomab tiuxetan",{"EARLY_PHASE1":2792,"PHASE1":2794,"PHASE2":2796,"PHASE3":2807,"PHASE4":2809,"NA":2811},{"trials":2793,"activeCount":94},[],{"trials":2795,"activeCount":94},[],{"trials":2797,"activeCount":94},[2798],{"nctId":2799,"briefTitle":2800,"status":785,"phases":2801,"primaryCompletion":2802,"completion":2077,"start":2803,"enrollment":16,"conditions":2804,"interventions":2806},"NCT00386321","Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma",[83],"2007-07","2006-04",[2805],"Diffuse Large B-cell Lymphoma",[2790],{"trials":2808,"activeCount":94},[],{"trials":2810,"activeCount":94},[],{"trials":2812,"activeCount":94},[],{"intervention":2814,"totalTrials":90,"cells":2815},"glutathione",{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2828,"PHASE3":2830,"PHASE4":2832,"NA":2834},{"trials":2817,"activeCount":94},[],{"trials":2819,"activeCount":94},[2820],{"nctId":2821,"briefTitle":2822,"status":693,"phases":2823,"primaryCompletion":776,"completion":752,"start":2824,"enrollment":887,"conditions":2825,"interventions":2827},"NCT01016080","Role of Oral Glutathione in Skin Whitening",[82],"2009-02",[2826],"Skin Whitening",[2814],{"trials":2829,"activeCount":94},[],{"trials":2831,"activeCount":94},[],{"trials":2833,"activeCount":94},[],{"trials":2835,"activeCount":94},[],{"intervention":2837,"totalTrials":90,"cells":2838},"ChulaCov19 BNA159 mRNA vaccine",{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2858,"PHASE3":2860,"PHASE4":2862,"NA":2864},{"trials":2840,"activeCount":94},[],{"trials":2842,"activeCount":94},[2843],{"nctId":2844,"briefTitle":2845,"status":429,"phases":2846,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":777,"conditions":2849,"interventions":2857},"NCT05231369","Safety and Immunogenicity of ChulaCov19 BNA159 mRNA Vaccine",[82],"2023-07-01","2022-12-14",[2850,2851,2852,2853,2854,2855,2856],"Safety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine","Tolerability of 25 ug of ChulaCov19-BNA159 mRNA Vaccine","Immune Response of 25 ug of ChulaCov19-BNA159 mRNA Vaccine","Safety of 50 ug of ChulaCov19-BNA159 mRNA Vaccine","Tolerability of 50 ug of ChulaCov19-BNA159 mRNA Vaccine","Immune Response of 50 ug of ChulaCov19-BNA159 mRNA Vaccine","Assess Which Dose is Appropriate to Use",[2837],{"trials":2859,"activeCount":94},[],{"trials":2861,"activeCount":94},[],{"trials":2863,"activeCount":94},[],{"trials":2865,"activeCount":94},[],{"intervention":2867,"totalTrials":90,"cells":2868},"Curcumin mouthwash",{"EARLY_PHASE1":2869,"PHASE1":2881,"PHASE2":2883,"PHASE3":2885,"PHASE4":2887,"NA":2889},{"trials":2870,"activeCount":94},[2871],{"nctId":2872,"briefTitle":2873,"status":693,"phases":2874,"primaryCompletion":2875,"completion":2875,"start":2876,"enrollment":1211,"conditions":2877,"interventions":2880},"NCT05147376","Effectiveness of a Curcumin Mouthwash in Preventing Traumatic Ulcers in Patients With Fixed Orthodontic Appliances",[81],"2023-08-07","2022-02-21",[2878,2879],"Oral Ulcer","Orthodontic Appliances, Fixed",[2867],{"trials":2882,"activeCount":94},[],{"trials":2884,"activeCount":94},[],{"trials":2886,"activeCount":94},[],{"trials":2888,"activeCount":94},[],{"trials":2890,"activeCount":94},[],{"intervention":2892,"totalTrials":406,"cells":2893},"Dydrogesterone",{"EARLY_PHASE1":2894,"PHASE1":2896,"PHASE2":2898,"PHASE3":2900,"PHASE4":2902,"NA":2921},{"trials":2895,"activeCount":94},[],{"trials":2897,"activeCount":94},[],{"trials":2899,"activeCount":94},[],{"trials":2901,"activeCount":94},[],{"trials":2903,"activeCount":94},[2904,2913],{"nctId":2905,"briefTitle":2906,"status":693,"phases":2907,"primaryCompletion":2908,"completion":2908,"start":2909,"enrollment":740,"conditions":2910,"interventions":2912},"NCT04788108","Oral Progesterone for Prevention of Miscarriage in Threatened Abortion",[85],"2022-08-31","2021-08-01",[2911],"Threatened Abortion",[2892],{"nctId":2914,"briefTitle":2915,"status":693,"phases":2916,"primaryCompletion":2917,"completion":2917,"start":2918,"enrollment":8,"conditions":2919,"interventions":2920},"NCT03935152","Oral Dydrogesterone in the Management of Preterm Labor",[85],"2020-05-31","2019-05-11",[1045],[2892],{"trials":2922,"activeCount":94},[2923],{"nctId":2924,"briefTitle":2925,"status":693,"phases":2926,"primaryCompletion":1389,"completion":1389,"start":2927,"enrollment":8,"conditions":2928,"interventions":2929},"NCT02262481","Oral Progestogen Supplementation in the Prevention of Recurrent Uterine Contraction in Preterm Labor",[86],"2014-08",[1045],[2930],"dydrogesterone",{"intervention":2932,"totalTrials":159,"cells":2933},"Everolimus",{"EARLY_PHASE1":2934,"PHASE1":2936,"PHASE2":2938,"PHASE3":2940,"PHASE4":2942,"NA":2944},{"trials":2935,"activeCount":94},[],{"trials":2937,"activeCount":94},[],{"trials":2939,"activeCount":94},[],{"trials":2941,"activeCount":94},[],{"trials":2943,"activeCount":94},[],{"trials":2945,"activeCount":94},[2946,2955],{"nctId":2947,"briefTitle":2948,"status":429,"phases":2949,"primaryCompletion":2950,"completion":2950,"start":750,"enrollment":470,"conditions":2951,"interventions":2953},"NCT02091973","MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Regimens in Kidney Transplantation",[86],"2015-12",[2952],"microRNA Profiles",[2932,2954],"Tacrolimus",{"nctId":2956,"briefTitle":2957,"status":693,"phases":2958,"primaryCompletion":2076,"completion":2076,"start":2959,"enrollment":204,"conditions":2960,"interventions":2962},"NCT01780948","Pharmacokinetic of Everolimus and Atorvastatin Co-administration",[86],"2012-09",[2961],"Difference of 12-hour AUC",[2963,2932],"Atorvastatin 20 mg",{"intervention":2965,"totalTrials":159,"cells":2966},"Vasopressor",{"EARLY_PHASE1":2967,"PHASE1":2969,"PHASE2":2971,"PHASE3":2973,"PHASE4":2975,"NA":2977},{"trials":2968,"activeCount":94},[],{"trials":2970,"activeCount":94},[],{"trials":2972,"activeCount":94},[],{"trials":2974,"activeCount":94},[],{"trials":2976,"activeCount":94},[],{"trials":2978,"activeCount":94},[2979,2992],{"nctId":2980,"briefTitle":2981,"status":693,"phases":2982,"primaryCompletion":2983,"completion":2984,"start":2985,"enrollment":470,"conditions":2986,"interventions":2990},"NCT04792424","No Monitoring of Post-filter Ionized Calcium in Regional Citrate Anticoagulation",[86],"2022-05-30","2022-06-15","2021-04-01",[2987,2988,2989],"Regional Citrate Anticoagulation","Ionized Calcium","Continuous Renal Replacement Therapy",[2965,2991],"Antibiotic",{"nctId":2993,"briefTitle":2994,"status":693,"phases":2995,"primaryCompletion":2996,"completion":2997,"start":2998,"enrollment":2999,"conditions":3000,"interventions":3001},"NCT03020407","The Randomized Controlled Trial of Inferior Vena Cava Ultrasound-guided Fluid Management in Septic Shock Resuscitation",[86],"2020-06-30","2020-07-31","2017-01-18",211,[28],[3002,2965],"Antibiotics",{"intervention":3004,"totalTrials":159,"cells":3005},"Ethinylestradiol",{"EARLY_PHASE1":3006,"PHASE1":3008,"PHASE2":3010,"PHASE3":3012,"PHASE4":3014,"NA":3016},{"trials":3007,"activeCount":94},[],{"trials":3009,"activeCount":94},[],{"trials":3011,"activeCount":94},[],{"trials":3013,"activeCount":94},[],{"trials":3015,"activeCount":94},[],{"trials":3017,"activeCount":94},[3018,3029],{"nctId":3019,"briefTitle":3020,"status":693,"phases":3021,"primaryCompletion":3022,"completion":3022,"start":2504,"enrollment":259,"conditions":3023,"interventions":3027},"NCT06396208","\"Quick-starting\" of a Quadriphasic Contraceptive Pills, 1 - 3 mg Estradiol Valerate\u002F 2 - 3 mg Dienogest VS 20 mcg Ethinylestradiol\u002F75 mcg Gestodene Focusing on Ovulation Inhibition",[86],"2024-10-31",[3024,3025,3026],"Ultrasound Finding: Ovulation Inhibition, Ovarian Activities","Cervical Mucus","Serum Hormonal Profile",[3028,3004],"Quadriphasic Estradiol valerate 1 - 3 mg\u002F Dienogest 2 - 3 mg",{"nctId":3030,"briefTitle":3031,"status":693,"phases":3032,"primaryCompletion":3033,"completion":3033,"start":2504,"enrollment":3034,"conditions":3035,"interventions":3036},"NCT06396221","\"Quick-starting\" of a New Combined Hormonal Contraceptive Pills, 15 mg Estetrol\u002F3 mg Drospirenone VS 20 mcg Ethinylestradiol\u002F75 mcg Gestodene Focusing on Ovulation Inhibition",[86],"2024-09-30",36,[3024,3025,3026],[3037,3004],"Estetrol 15 mg\u002FDrospirenone 3 mg",{"intervention":3039,"totalTrials":90,"cells":3040},"Voriconazole",{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3045,"PHASE3":3047,"PHASE4":3049,"NA":3051},{"trials":3042,"activeCount":94},[],{"trials":3044,"activeCount":94},[],{"trials":3046,"activeCount":94},[],{"trials":3048,"activeCount":94},[],{"trials":3050,"activeCount":94},[],{"trials":3052,"activeCount":94},[3053],{"nctId":3054,"briefTitle":3055,"status":429,"phases":3056,"primaryCompletion":3057,"completion":886,"start":3058,"enrollment":3059,"conditions":3060,"interventions":3062},"NCT03260634","The Study of Voriconazole Trough Level in the First Two Weeks After Administration in King Chulalongkorn Memorial Hospital.",[],"2017-10-01","2016-01-01",92,[3039,3061],"Fungal Infection",[3039],{"intervention":3064,"totalTrials":90,"cells":3065},"HBsAg positive kidney allograft donor",{"EARLY_PHASE1":3066,"PHASE1":3068,"PHASE2":3070,"PHASE3":3072,"PHASE4":3074,"NA":3076},{"trials":3067,"activeCount":94},[],{"trials":3069,"activeCount":94},[],{"trials":3071,"activeCount":94},[],{"trials":3073,"activeCount":94},[],{"trials":3075,"activeCount":94},[],{"trials":3077,"activeCount":94},[3078],{"nctId":3079,"briefTitle":3080,"status":429,"phases":3081,"primaryCompletion":1939,"start":3082,"enrollment":740,"conditions":3083,"interventions":3086},"NCT02044588","Hepatitis B Antigen Kidney Graft Into Protective Level Hepatitis B Antibody Recipients",[],"2000-01",[3084,3085],"HBsAg(+) Donor Kidney Allograft","HBsAg(-) Donor Kidney Allograft",[3064],{"intervention":3088,"totalTrials":90,"cells":3089},"progesterone",{"EARLY_PHASE1":3090,"PHASE1":3092,"PHASE2":3094,"PHASE3":3096,"PHASE4":3098,"NA":3100},{"trials":3091,"activeCount":94},[],{"trials":3093,"activeCount":94},[],{"trials":3095,"activeCount":94},[],{"trials":3097,"activeCount":94},[],{"trials":3099,"activeCount":94},[],{"trials":3101,"activeCount":94},[3102],{"nctId":3103,"briefTitle":3104,"status":693,"phases":3105,"primaryCompletion":3106,"completion":3107,"start":3108,"enrollment":753,"conditions":3109,"interventions":3110},"NCT03202836","Vaginal Progesterone Supplementation in the Management of Preterm Labor",[86],"2018-07-30","2018-07-31","2017-06-29",[1045],[3088,3111,3112],"Tocolytics","Steroids",{"intervention":3111,"totalTrials":90,"cells":3114},{"EARLY_PHASE1":3115,"PHASE1":3117,"PHASE2":3119,"PHASE3":3121,"PHASE4":3123,"NA":3125},{"trials":3116,"activeCount":94},[],{"trials":3118,"activeCount":94},[],{"trials":3120,"activeCount":94},[],{"trials":3122,"activeCount":94},[],{"trials":3124,"activeCount":94},[],{"trials":3126,"activeCount":94},[3127],{"nctId":3103,"briefTitle":3104,"status":693,"phases":3128,"primaryCompletion":3106,"completion":3107,"start":3108,"enrollment":753,"conditions":3129,"interventions":3130},[86],[1045],[3088,3111,3112],{"intervention":3112,"totalTrials":90,"cells":3132},{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3139,"PHASE4":3141,"NA":3143},{"trials":3134,"activeCount":94},[],{"trials":3136,"activeCount":94},[],{"trials":3138,"activeCount":94},[],{"trials":3140,"activeCount":94},[],{"trials":3142,"activeCount":94},[],{"trials":3144,"activeCount":94},[3145],{"nctId":3103,"briefTitle":3104,"status":693,"phases":3146,"primaryCompletion":3106,"completion":3107,"start":3108,"enrollment":753,"conditions":3147,"interventions":3148},[86],[1045],[3088,3111,3112],{"intervention":3150,"totalTrials":90,"cells":3151},"IV Dexamethasone",{"EARLY_PHASE1":3152,"PHASE1":3154,"PHASE2":3156,"PHASE3":3158,"PHASE4":3160,"NA":3162},{"trials":3153,"activeCount":94},[],{"trials":3155,"activeCount":94},[],{"trials":3157,"activeCount":94},[],{"trials":3159,"activeCount":94},[],{"trials":3161,"activeCount":94},[],{"trials":3163,"activeCount":94},[3164],{"nctId":3165,"briefTitle":3166,"status":693,"phases":3167,"primaryCompletion":3168,"completion":3168,"start":3057,"enrollment":3169,"conditions":3170,"interventions":3173},"NCT03296358","Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.",[86],"2019-10-31",75,[3171,3172],"Urticaria","Allergy",[3150,3174],"Oral prednisolone",{"intervention":3174,"totalTrials":90,"cells":3176},{"EARLY_PHASE1":3177,"PHASE1":3179,"PHASE2":3181,"PHASE3":3183,"PHASE4":3185,"NA":3187},{"trials":3178,"activeCount":94},[],{"trials":3180,"activeCount":94},[],{"trials":3182,"activeCount":94},[],{"trials":3184,"activeCount":94},[],{"trials":3186,"activeCount":94},[],{"trials":3188,"activeCount":94},[3189],{"nctId":3165,"briefTitle":3166,"status":693,"phases":3190,"primaryCompletion":3168,"completion":3168,"start":3057,"enrollment":3169,"conditions":3191,"interventions":3192},[86],[3171,3172],[3150,3174],{"intervention":3194,"totalTrials":90,"cells":3195},"Diacerein",{"EARLY_PHASE1":3196,"PHASE1":3198,"PHASE2":3200,"PHASE3":3202,"PHASE4":3204,"NA":3206},{"trials":3197,"activeCount":94},[],{"trials":3199,"activeCount":94},[],{"trials":3201,"activeCount":94},[],{"trials":3203,"activeCount":94},[],{"trials":3205,"activeCount":94},[],{"trials":3207,"activeCount":94},[3208],{"nctId":3209,"briefTitle":3210,"status":693,"phases":3211,"primaryCompletion":2997,"completion":2997,"start":3212,"enrollment":1966,"conditions":3213,"interventions":3216},"NCT04351100","Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients",[],"2019-10-01",[3214,3215,3194],"Ocular Surface Disease","Osteoarthritis",[3194],{"intervention":2954,"totalTrials":90,"cells":3218},{"EARLY_PHASE1":3219,"PHASE1":3221,"PHASE2":3223,"PHASE3":3225,"PHASE4":3227,"NA":3229},{"trials":3220,"activeCount":94},[],{"trials":3222,"activeCount":94},[],{"trials":3224,"activeCount":94},[],{"trials":3226,"activeCount":94},[],{"trials":3228,"activeCount":94},[],{"trials":3230,"activeCount":94},[3231],{"nctId":2947,"briefTitle":2948,"status":429,"phases":3232,"primaryCompletion":2950,"completion":2950,"start":750,"enrollment":470,"conditions":3233,"interventions":3234},[86],[2952],[2932,2954],{"intervention":3236,"totalTrials":90,"cells":3237},"Anti-Bacterial Agents",{"EARLY_PHASE1":3238,"PHASE1":3240,"PHASE2":3242,"PHASE3":3244,"PHASE4":3246,"NA":3248},{"trials":3239,"activeCount":94},[],{"trials":3241,"activeCount":94},[],{"trials":3243,"activeCount":94},[],{"trials":3245,"activeCount":94},[],{"trials":3247,"activeCount":94},[],{"trials":3249,"activeCount":94},[3250],{"nctId":3251,"briefTitle":3252,"status":693,"phases":3253,"primaryCompletion":3254,"completion":3254,"start":811,"enrollment":3255,"conditions":3256,"interventions":3257},"NCT02730117","Furosemide Stress Test Guiding Initiation of Renal Replacement Therapy",[86],"2017-07",118,[18],[3236,3258],"Vasopressors",{"intervention":3258,"totalTrials":90,"cells":3260},{"EARLY_PHASE1":3261,"PHASE1":3263,"PHASE2":3265,"PHASE3":3267,"PHASE4":3269,"NA":3271},{"trials":3262,"activeCount":94},[],{"trials":3264,"activeCount":94},[],{"trials":3266,"activeCount":94},[],{"trials":3268,"activeCount":94},[],{"trials":3270,"activeCount":94},[],{"trials":3272,"activeCount":94},[3273],{"nctId":3251,"briefTitle":3252,"status":693,"phases":3274,"primaryCompletion":3254,"completion":3254,"start":811,"enrollment":3255,"conditions":3275,"interventions":3276},[86],[18],[3236,3258],{"intervention":3278,"totalTrials":90,"cells":3279},"HPV-6\u002F11\u002F16\u002F18 vaccine",{"EARLY_PHASE1":3280,"PHASE1":3282,"PHASE2":3284,"PHASE3":3286,"PHASE4":3288,"NA":3290},{"trials":3281,"activeCount":94},[],{"trials":3283,"activeCount":94},[],{"trials":3285,"activeCount":94},[],{"trials":3287,"activeCount":94},[],{"trials":3289,"activeCount":94},[],{"trials":3291,"activeCount":94},[3292],{"nctId":3293,"briefTitle":3294,"status":429,"phases":3295,"primaryCompletion":2927,"completion":1939,"start":3296,"enrollment":887,"conditions":3297,"interventions":3300},"NCT01298869","The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6\u002F11\u002F16\u002F18) in Chronic Kidney Disease (CKD) Patients",[],"2011-02",[3298,3299],"Chronic Kidney Disease, Stage IV (Severe)","Chronic Kidney Disease, Stage V",[3278],{"intervention":3302,"totalTrials":90,"cells":3303},"Renin-Angiotensin System Inhibitor",{"EARLY_PHASE1":3304,"PHASE1":3306,"PHASE2":3308,"PHASE3":3310,"PHASE4":3312,"NA":3314},{"trials":3305,"activeCount":94},[],{"trials":3307,"activeCount":94},[],{"trials":3309,"activeCount":94},[],{"trials":3311,"activeCount":94},[],{"trials":3313,"activeCount":94},[],{"trials":3315,"activeCount":94},[3316],{"nctId":3317,"briefTitle":3318,"status":693,"phases":3319,"primaryCompletion":3320,"completion":3321,"start":3058,"enrollment":3322,"conditions":3323,"interventions":3325},"NCT06382571","Factors Associated With Sub - Targeted Therapeutic Dose Of Renin - Angiotensin Blockage Among Chronic Heart Failure With Reduced Ejection Fraction Patients",[],"2020-12-31","2021-12-31",396,[3324],"Heart Failure With Reduced Ejection Fraction",[3302],{"intervention":3327,"totalTrials":90,"cells":3328},"Nalbuphine Hydrochloride 10 MG\u002FML",{"EARLY_PHASE1":3329,"PHASE1":3331,"PHASE2":3333,"PHASE3":3335,"PHASE4":3337,"NA":3339},{"trials":3330,"activeCount":94},[],{"trials":3332,"activeCount":94},[],{"trials":3334,"activeCount":94},[],{"trials":3336,"activeCount":94},[],{"trials":3338,"activeCount":94},[],{"trials":3340,"activeCount":94},[3341],{"nctId":3342,"briefTitle":3343,"status":693,"phases":3344,"primaryCompletion":3345,"completion":3346,"start":3347,"enrollment":932,"conditions":3348,"interventions":3350},"NCT06153602","Effectiveness of Nalbuphine as an Adjuvant to Subarachnoid Block on Postoperative Analgesia in TURP Surgery",[86],"2024-11-27","2024-11-28","2023-12-07",[3349],"Transurethral Resection of Prostate",[3327,3351,3352,3353,3354,3355],"Sodium Chloride 0.9 % in 5 ML","Bupivacaine Hydrochloride, Spinal","Nalbuphine Hcl 10Mg\u002FMl Inj","Acetaminophen 500Mg Tab","Ondansetron 8mg",{"intervention":3351,"totalTrials":90,"cells":3357},{"EARLY_PHASE1":3358,"PHASE1":3360,"PHASE2":3362,"PHASE3":3364,"PHASE4":3366,"NA":3368},{"trials":3359,"activeCount":94},[],{"trials":3361,"activeCount":94},[],{"trials":3363,"activeCount":94},[],{"trials":3365,"activeCount":94},[],{"trials":3367,"activeCount":94},[],{"trials":3369,"activeCount":94},[3370],{"nctId":3342,"briefTitle":3343,"status":693,"phases":3371,"primaryCompletion":3345,"completion":3346,"start":3347,"enrollment":932,"conditions":3372,"interventions":3373},[86],[3349],[3327,3351,3352,3353,3354,3355],{"intervention":3352,"totalTrials":90,"cells":3375},{"EARLY_PHASE1":3376,"PHASE1":3378,"PHASE2":3380,"PHASE3":3382,"PHASE4":3384,"NA":3386},{"trials":3377,"activeCount":94},[],{"trials":3379,"activeCount":94},[],{"trials":3381,"activeCount":94},[],{"trials":3383,"activeCount":94},[],{"trials":3385,"activeCount":94},[],{"trials":3387,"activeCount":94},[3388],{"nctId":3342,"briefTitle":3343,"status":693,"phases":3389,"primaryCompletion":3345,"completion":3346,"start":3347,"enrollment":932,"conditions":3390,"interventions":3391},[86],[3349],[3327,3351,3352,3353,3354,3355],{"intervention":3353,"totalTrials":90,"cells":3393},{"EARLY_PHASE1":3394,"PHASE1":3396,"PHASE2":3398,"PHASE3":3400,"PHASE4":3402,"NA":3404},{"trials":3395,"activeCount":94},[],{"trials":3397,"activeCount":94},[],{"trials":3399,"activeCount":94},[],{"trials":3401,"activeCount":94},[],{"trials":3403,"activeCount":94},[],{"trials":3405,"activeCount":94},[3406],{"nctId":3342,"briefTitle":3343,"status":693,"phases":3407,"primaryCompletion":3345,"completion":3346,"start":3347,"enrollment":932,"conditions":3408,"interventions":3409},[86],[3349],[3327,3351,3352,3353,3354,3355],{"intervention":3354,"totalTrials":90,"cells":3411},{"EARLY_PHASE1":3412,"PHASE1":3414,"PHASE2":3416,"PHASE3":3418,"PHASE4":3420,"NA":3422},{"trials":3413,"activeCount":94},[],{"trials":3415,"activeCount":94},[],{"trials":3417,"activeCount":94},[],{"trials":3419,"activeCount":94},[],{"trials":3421,"activeCount":94},[],{"trials":3423,"activeCount":94},[3424],{"nctId":3342,"briefTitle":3343,"status":693,"phases":3425,"primaryCompletion":3345,"completion":3346,"start":3347,"enrollment":932,"conditions":3426,"interventions":3427},[86],[3349],[3327,3351,3352,3353,3354,3355],{"intervention":3355,"totalTrials":90,"cells":3429},{"EARLY_PHASE1":3430,"PHASE1":3432,"PHASE2":3434,"PHASE3":3436,"PHASE4":3438,"NA":3440},{"trials":3431,"activeCount":94},[],{"trials":3433,"activeCount":94},[],{"trials":3435,"activeCount":94},[],{"trials":3437,"activeCount":94},[],{"trials":3439,"activeCount":94},[],{"trials":3441,"activeCount":94},[3442],{"nctId":3342,"briefTitle":3343,"status":693,"phases":3443,"primaryCompletion":3345,"completion":3346,"start":3347,"enrollment":932,"conditions":3444,"interventions":3445},[86],[3349],[3327,3351,3352,3353,3354,3355],{"intervention":2963,"totalTrials":90,"cells":3447},{"EARLY_PHASE1":3448,"PHASE1":3450,"PHASE2":3452,"PHASE3":3454,"PHASE4":3456,"NA":3458},{"trials":3449,"activeCount":94},[],{"trials":3451,"activeCount":94},[],{"trials":3453,"activeCount":94},[],{"trials":3455,"activeCount":94},[],{"trials":3457,"activeCount":94},[],{"trials":3459,"activeCount":94},[3460],{"nctId":2956,"briefTitle":2957,"status":693,"phases":3461,"primaryCompletion":2076,"completion":2076,"start":2959,"enrollment":204,"conditions":3462,"interventions":3463},[86],[2961],[2963,2932],{"intervention":3465,"totalTrials":90,"cells":3466},"Benzoyl Peroxide gel",{"EARLY_PHASE1":3467,"PHASE1":3469,"PHASE2":3471,"PHASE3":3473,"PHASE4":3475,"NA":3477},{"trials":3468,"activeCount":94},[],{"trials":3470,"activeCount":94},[],{"trials":3472,"activeCount":94},[],{"trials":3474,"activeCount":94},[],{"trials":3476,"activeCount":94},[],{"trials":3478,"activeCount":94},[3479],{"nctId":3480,"briefTitle":3481,"status":693,"phases":3482,"primaryCompletion":3483,"completion":3483,"start":1067,"enrollment":11,"conditions":3484,"interventions":3486},"NCT01472900","2940nm Er:YAG Laser Versus Benzoyl Peroxide Gel for the Treatment of Inflammatory Acne",[86],"2012-04",[3485],"Acne Vulgaris",[3465],{"intervention":3488,"totalTrials":90,"cells":3489},"Artificial salivary containing cumin and ginger extract",{"EARLY_PHASE1":3490,"PHASE1":3492,"PHASE2":3494,"PHASE3":3496,"PHASE4":3498,"NA":3500},{"trials":3491,"activeCount":94},[],{"trials":3493,"activeCount":94},[],{"trials":3495,"activeCount":94},[],{"trials":3497,"activeCount":94},[],{"trials":3499,"activeCount":94},[],{"trials":3501,"activeCount":94},[3502],{"nctId":3503,"briefTitle":3504,"status":429,"phases":3505,"primaryCompletion":3506,"completion":3507,"start":3508,"enrollment":1940,"conditions":3509,"interventions":3510},"NCT04997889","Efficacy (Preliminary) and Safety of Artificial Salivary Containing Cumin and Ginger Extract in Healthy Volunteer",[86],"2024-06-30","2024-07-31","2024-02-15",[495],[3488],{"intervention":3512,"totalTrials":90,"cells":3513},"PEG-IFN and entecavir",{"EARLY_PHASE1":3514,"PHASE1":3516,"PHASE2":3518,"PHASE3":3520,"PHASE4":3522,"NA":3524},{"trials":3515,"activeCount":94},[],{"trials":3517,"activeCount":94},[],{"trials":3519,"activeCount":94},[],{"trials":3521,"activeCount":94},[],{"trials":3523,"activeCount":94},[],{"trials":3525,"activeCount":94},[3526],{"nctId":3527,"briefTitle":3528,"status":429,"phases":3529,"primaryCompletion":2027,"completion":3530,"start":3531,"enrollment":3532,"conditions":3533,"interventions":3535},"NCT01243281","Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B",[86],"2013-12","2011-03",126,[3534],"Chronic Hepatitis B",[3512],{"intervention":3537,"totalTrials":90,"cells":3538},"Tacrolimus C12",{"EARLY_PHASE1":3539,"PHASE1":3541,"PHASE2":3543,"PHASE3":3545,"PHASE4":3547,"NA":3549},{"trials":3540,"activeCount":94},[],{"trials":3542,"activeCount":94},[],{"trials":3544,"activeCount":94},[],{"trials":3546,"activeCount":94},[],{"trials":3548,"activeCount":94},[],{"trials":3550,"activeCount":94},[3551],{"nctId":3552,"briefTitle":3553,"status":429,"phases":3554,"primaryCompletion":837,"completion":1389,"start":1736,"enrollment":887,"conditions":3555,"interventions":3557},"NCT02356146","First Tacrolimus Dose Trough Level is Better Than CYP3A5 Genotyping in Tacrolimus Dose Prediction",[],[3556],"Kidney Transplantation Recipients",[3537],{"intervention":2991,"totalTrials":90,"cells":3559},{"EARLY_PHASE1":3560,"PHASE1":3562,"PHASE2":3564,"PHASE3":3566,"PHASE4":3568,"NA":3570},{"trials":3561,"activeCount":94},[],{"trials":3563,"activeCount":94},[],{"trials":3565,"activeCount":94},[],{"trials":3567,"activeCount":94},[],{"trials":3569,"activeCount":94},[],{"trials":3571,"activeCount":94},[3572],{"nctId":2980,"briefTitle":2981,"status":693,"phases":3573,"primaryCompletion":2983,"completion":2984,"start":2985,"enrollment":470,"conditions":3574,"interventions":3575},[86],[2987,2988,2989],[2965,2991],{"intervention":3577,"totalTrials":90,"cells":3578},"aspirin, NSAIDs, paracetamol",{"EARLY_PHASE1":3579,"PHASE1":3581,"PHASE2":3583,"PHASE3":3585,"PHASE4":3587,"NA":3589},{"trials":3580,"activeCount":94},[],{"trials":3582,"activeCount":94},[],{"trials":3584,"activeCount":94},[],{"trials":3586,"activeCount":94},[],{"trials":3588,"activeCount":94},[],{"trials":3590,"activeCount":94},[3591],{"nctId":3592,"briefTitle":3593,"status":693,"phases":3594,"primaryCompletion":3595,"completion":3596,"start":3597,"enrollment":3598,"conditions":3599,"interventions":3608},"NCT03849625","Characteristics of Patients Diagnosed With NSAID Sensitivity in Thailand",[],"2020-02-28","2020-03-31","2015-05-01",158,[3600,3601,3602,3603,3604,3605,3606,3607],"Aspirin Sensitivity","Aspirin-exacerbated Respiratory Disease","Aspirin-Induced Angioedema-Urticaria","Aspirin Allergy","NSAID-Induced Asthma","NSAID-Induced Angioedema-Urticaria","NSAID-Induced Anaphylactoid Reaction","Aspirin-Induced Anaphylactoid Reaction",[3577],{"intervention":3610,"totalTrials":90,"cells":3611},"DNA sequencing",{"EARLY_PHASE1":3612,"PHASE1":3614,"PHASE2":3616,"PHASE3":3618,"PHASE4":3620,"NA":3622},{"trials":3613,"activeCount":94},[],{"trials":3615,"activeCount":94},[],{"trials":3617,"activeCount":94},[],{"trials":3619,"activeCount":94},[],{"trials":3621,"activeCount":94},[],{"trials":3623,"activeCount":94},[3624],{"nctId":3625,"briefTitle":3626,"status":429,"phases":3627,"primaryCompletion":811,"completion":1693,"start":3628,"enrollment":182,"conditions":3629,"interventions":3630},"NCT02720861","Prevalence of Genetic Polymporphism on RNF213 rs112735431 Gene in Non-cardioemboli Ischemic Cerebrovascular Disease",[],"2015-03",[2030],[3610],{"intervention":3632,"totalTrials":90,"cells":3633},"Low bolus concentration and volume",{"EARLY_PHASE1":3634,"PHASE1":3636,"PHASE2":3638,"PHASE3":3640,"PHASE4":3642,"NA":3644},{"trials":3635,"activeCount":94},[],{"trials":3637,"activeCount":94},[],{"trials":3639,"activeCount":94},[],{"trials":3641,"activeCount":94},[],{"trials":3643,"activeCount":94},[],{"trials":3645,"activeCount":94},[3646],{"nctId":3647,"briefTitle":3648,"status":693,"phases":3649,"primaryCompletion":3650,"completion":3651,"start":3652,"enrollment":3653,"conditions":3654,"interventions":3656},"NCT06179628","Low vs Standard Local Anesthetics Boluses for Continuous Adductor Canal Block in Total Knee Arthroplasty",[86],"2024-07-17","2024-07-24","2023-12-09",140,[3655],"Knee Arthropathy",[3632],{"intervention":3028,"totalTrials":90,"cells":3658},{"EARLY_PHASE1":3659,"PHASE1":3661,"PHASE2":3663,"PHASE3":3665,"PHASE4":3667,"NA":3669},{"trials":3660,"activeCount":94},[],{"trials":3662,"activeCount":94},[],{"trials":3664,"activeCount":94},[],{"trials":3666,"activeCount":94},[],{"trials":3668,"activeCount":94},[],{"trials":3670,"activeCount":94},[3671],{"nctId":3019,"briefTitle":3020,"status":693,"phases":3672,"primaryCompletion":3022,"completion":3022,"start":2504,"enrollment":259,"conditions":3673,"interventions":3674},[86],[3024,3025,3026],[3028,3004],{"intervention":3676,"totalTrials":90,"cells":3677},"a live attenuated chimeric JE vaccine",{"EARLY_PHASE1":3678,"PHASE1":3680,"PHASE2":3682,"PHASE3":3684,"PHASE4":3686,"NA":3688},{"trials":3679,"activeCount":94},[],{"trials":3681,"activeCount":94},[],{"trials":3683,"activeCount":94},[],{"trials":3685,"activeCount":94},[],{"trials":3687,"activeCount":94},[],{"trials":3689,"activeCount":94},[3690],{"nctId":3691,"briefTitle":3692,"status":693,"phases":3693,"primaryCompletion":812,"completion":812,"start":3530,"enrollment":470,"conditions":3694,"interventions":3696},"NCT02602652","Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine",[86],[3695],"Japanese Encephalitis",[3676],{"intervention":3002,"totalTrials":90,"cells":3698},{"EARLY_PHASE1":3699,"PHASE1":3701,"PHASE2":3703,"PHASE3":3705,"PHASE4":3707,"NA":3709},{"trials":3700,"activeCount":94},[],{"trials":3702,"activeCount":94},[],{"trials":3704,"activeCount":94},[],{"trials":3706,"activeCount":94},[],{"trials":3708,"activeCount":94},[],{"trials":3710,"activeCount":94},[3711],{"nctId":2993,"briefTitle":2994,"status":693,"phases":3712,"primaryCompletion":2996,"completion":2997,"start":2998,"enrollment":2999,"conditions":3713,"interventions":3714},[86],[28],[3002,2965],{"intervention":3716,"totalTrials":90,"cells":3717},"Eptinezumab",{"EARLY_PHASE1":3718,"PHASE1":3720,"PHASE2":3722,"PHASE3":3724,"PHASE4":3726,"NA":3728},{"trials":3719,"activeCount":94},[],{"trials":3721,"activeCount":94},[],{"trials":3723,"activeCount":94},[],{"trials":3725,"activeCount":94},[],{"trials":3727,"activeCount":94},[],{"trials":3729,"activeCount":94},[3730],{"nctId":3731,"briefTitle":3732,"status":693,"phases":3733,"primaryCompletion":3734,"completion":3735,"start":3736,"enrollment":615,"conditions":3737,"interventions":3741},"NCT07035197","Facilitators and Barriers to Eptinezumab Administration in Thailand",[],"2026-01-31","2026-03-31","2025-08-25",[3738,3739,3740],"Migraine","Treatment","Treatment Refusal",[3716],{"intervention":3037,"totalTrials":90,"cells":3743},{"EARLY_PHASE1":3744,"PHASE1":3746,"PHASE2":3748,"PHASE3":3750,"PHASE4":3752,"NA":3754},{"trials":3745,"activeCount":94},[],{"trials":3747,"activeCount":94},[],{"trials":3749,"activeCount":94},[],{"trials":3751,"activeCount":94},[],{"trials":3753,"activeCount":94},[],{"trials":3755,"activeCount":94},[3756],{"nctId":3030,"briefTitle":3031,"status":693,"phases":3757,"primaryCompletion":3033,"completion":3033,"start":2504,"enrollment":3034,"conditions":3758,"interventions":3759},[86],[3024,3025,3026],[3037,3004],{"intervention":3761,"totalTrials":90,"cells":3762},"Antihypertensive meds",{"EARLY_PHASE1":3763,"PHASE1":3765,"PHASE2":3767,"PHASE3":3769,"PHASE4":3771,"NA":3773},{"trials":3764,"activeCount":94},[],{"trials":3766,"activeCount":94},[],{"trials":3768,"activeCount":94},[],{"trials":3770,"activeCount":94},[],{"trials":3772,"activeCount":94},[],{"trials":3774,"activeCount":94},[3775],{"nctId":3776,"briefTitle":3777,"status":693,"phases":3778,"primaryCompletion":2950,"completion":2950,"start":3779,"enrollment":3780,"conditions":3781,"interventions":3785},"NCT02534324","The Effect of Pre-discharge Blood Pressure of Patients With Asymptomatic Severe Hypertension in Emergency Department",[],"2015-09",146,[3782,3783,3784],"Hypertension","Emergencies","Asymptomatic Conditions",[3761],{"intervention":3787,"totalTrials":90,"cells":3788},"Amorolfine 5% Nail Lacquer",{"EARLY_PHASE1":3789,"PHASE1":3791,"PHASE2":3793,"PHASE3":3795,"PHASE4":3797,"NA":3799},{"trials":3790,"activeCount":94},[],{"trials":3792,"activeCount":94},[],{"trials":3794,"activeCount":94},[],{"trials":3796,"activeCount":94},[],{"trials":3798,"activeCount":94},[],{"trials":3800,"activeCount":94},[3801],{"nctId":3802,"briefTitle":3803,"status":693,"phases":3804,"primaryCompletion":2412,"completion":2121,"start":3805,"enrollment":3806,"conditions":3807,"interventions":3809},"NCT03098342","Comparison of Efficacy and Safety Between Methylene Blue-mediated Photodynamic Therapy and 5% Amorolfine Nail Lacquer for Toenail Onychomycosis Treatment",[86],"2017-06-01",27,[3808],"Onychomycosis of Toenail",[3787],{"intervention":3811,"totalTrials":90,"cells":3812},"ceftazidime+ciprofloxacin",{"EARLY_PHASE1":3813,"PHASE1":3815,"PHASE2":3817,"PHASE3":3819,"PHASE4":3821,"NA":3823},{"trials":3814,"activeCount":94},[],{"trials":3816,"activeCount":94},[],{"trials":3818,"activeCount":94},[],{"trials":3820,"activeCount":94},[],{"trials":3822,"activeCount":94},[],{"trials":3824,"activeCount":94},[3825],{"nctId":3826,"briefTitle":3827,"status":693,"phases":3828,"primaryCompletion":3530,"completion":3530,"start":3829,"enrollment":3830,"conditions":3831,"interventions":3833},"NCT01785641","Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients",[86],"2012-12",300,[3832],"Peritonitis",[3811,3834,3835,3836],"ceftazidime monotherapy","cefazolin+gentamicin","cefazolin monotherapy",{"intervention":3834,"totalTrials":90,"cells":3838},{"EARLY_PHASE1":3839,"PHASE1":3841,"PHASE2":3843,"PHASE3":3845,"PHASE4":3847,"NA":3849},{"trials":3840,"activeCount":94},[],{"trials":3842,"activeCount":94},[],{"trials":3844,"activeCount":94},[],{"trials":3846,"activeCount":94},[],{"trials":3848,"activeCount":94},[],{"trials":3850,"activeCount":94},[3851],{"nctId":3826,"briefTitle":3827,"status":693,"phases":3852,"primaryCompletion":3530,"completion":3530,"start":3829,"enrollment":3830,"conditions":3853,"interventions":3854},[86],[3832],[3811,3834,3835,3836],{"intervention":3835,"totalTrials":90,"cells":3856},{"EARLY_PHASE1":3857,"PHASE1":3859,"PHASE2":3861,"PHASE3":3863,"PHASE4":3865,"NA":3867},{"trials":3858,"activeCount":94},[],{"trials":3860,"activeCount":94},[],{"trials":3862,"activeCount":94},[],{"trials":3864,"activeCount":94},[],{"trials":3866,"activeCount":94},[],{"trials":3868,"activeCount":94},[3869],{"nctId":3826,"briefTitle":3827,"status":693,"phases":3870,"primaryCompletion":3530,"completion":3530,"start":3829,"enrollment":3830,"conditions":3871,"interventions":3872},[86],[3832],[3811,3834,3835,3836],{"intervention":3836,"totalTrials":90,"cells":3874},{"EARLY_PHASE1":3875,"PHASE1":3877,"PHASE2":3879,"PHASE3":3881,"PHASE4":3883,"NA":3885},{"trials":3876,"activeCount":94},[],{"trials":3878,"activeCount":94},[],{"trials":3880,"activeCount":94},[],{"trials":3882,"activeCount":94},[],{"trials":3884,"activeCount":94},[],{"trials":3886,"activeCount":94},[3887],{"nctId":3826,"briefTitle":3827,"status":693,"phases":3888,"primaryCompletion":3530,"completion":3530,"start":3829,"enrollment":3830,"conditions":3889,"interventions":3890},[86],[3832],[3811,3834,3835,3836]]